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INTRODUCTION 
“Chronic obstructive pulmonary disease (COPD) is defined as a 
disease state characterized by persistent airflow limitation that is not fully 
reversible”1. COPD includes: 
1) “Emphysema, defined as abnormalpermanent enlargement of distal 
airspaces, distal to terminal bronchioles, accompanied by 
destruction of their walls and without obvious fibrosis”. 
2) “Chronic bronchitis, clinically defined as the presence of chronic 
productive cough on most days for three months, in each of two 
consecutive years, in a patient in whom other cause of chronic 
cough has been excluded”. 
COPD has been implicated as a leading cause for worldwide 
mortality and morbidity. Exposure to tobacco smoking, outdoor, 
occupational and indoor air pollution is directly related to the prevalence 
of COPD. Spirometry is essential for diagnosis of COPD. A post 
bronchodilator Forced expiratory volume in 1 second (FEV1) / Forced 
vital capacity(FVC) [FEV1/FVC] less than 0.70 is essential for the 
diagnosis of COPD. COPD has now been found to be a systemic disease 
which affects lungs as well as other organ systems. Global Initiative for 
Chronic Lung Disease (GOLD) uses FEV1 based staging system for 
assessing the severity of the disease. It has been found that FEV1 based 
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staging system correlates poorly with symptoms of the patient, frequency 
of exacerbation, quality of life and intolerance to exercise. The 
multidimensional grading system, BODE index (body mass index, 
airflow obstruction , dyspnea and exercise capacity ) has been shown  to 
be a better predictor for risk of death among COPD patients than FEV1. 
BODE index alsoprovides useful prognostic information.  
              Since COPD has been found to be associated with significant 
systemic inflammation, widespread research has been held in the field of 
biomarkers for COPD. Serum CRP levels have been found to be elevated 
even in stable COPD patients with no recent exacerbations. Basal CRP 
levels also helps in predicting overall mortality, mortality from cancer 
and cardiovascular diseases in patients with mild to moderate COPD. 
                For assessment of quality of life, various questionnaires have 
been developed which helps to establish the impact of the disease on 
patient’s life. 
              In this study, it has been hypothesized that BODE index is a 
better predictor of health status of the patient, quality of life as well as 
systemic inflammation as compared to the FEV1 based GOLD staging 
and aims to investigate the relationship of GOLD staging, BODE index 
with serum CRP levels, Quality of life, as well as prognostic factors in 
stable COPD patients. 
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
 To investigate the relationship of severity of airflow limitation as 
assigned by GOLD staging, and BODE index with serum  
C- reactive protein levels, Quality of life as well as with prognostic 
factors like disease duration, annual exacerbation and hospital 
admission rates in stable COPD patients. 
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LITERATURE 
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HISTORICAL REVIEW OF COPD 
 
The earliest references for emphysema dates back to 1679 which 
include Bonet’s description of voluminous lung; (Bonet 1679), 
Morgagni’s account of 19 cases in 1769 in which the lungs were 
described as turgid which was due to air and Baille who illustrated the 
emphysematous lung (Baille1789; Bishop1959). Laennec also gave 
beautiful description of emphysema in his “ Treatise of disease of chest” 
in which he emphasized that lungs were hyperinflated and did not empty 
well in emphysema (1821). He also gave a combined description of 
emphysema and chronic bronchitis. 
 
Significant understanding of the chronic bronchitis component of 
COPD was obtained following the pioneering work of Badham who 
described chronic bronchitis and bronchiolitis as disabling disorders 
(Badham 1814). He had used the term “catarrh”to refer the chronic cough 
and mucous hypersecretion which were cardinal symptoms of chronic 
bronchitis. 
 
 Spirometer was introduced by John Hutchinson in 1846 which is 
integral for the diagnosis as well as management of COPD . But this 
instrument could only measure vital capacity and it was not before 1947, 
when Timed vital capacity was introduced as a measure of airflow by 
5 
 
 
 
Tiffeneau. This work laid foundation to the concept of airflow velocity 
index which was put forward by Gansler and this later became the basis 
for FEV1 and FEV1/FVC percent. 
 
DEFINITION OF COPD 
 
            Even though several definitions exist for COPD, it would be 
unjustifiable to comment as one superior to other. The first definition 
came from the working group of American Thoracic Society (ATS) and 
the European Respiratory society (ERS). ATS 1995 had defined “COPD 
as a disease state characterized by the presence of airflow obstruction 
caused by chronic bronchitis or emphysema; the airflow obstruction is 
generally progressive, may be accompanied by airway hyper reactivity, 
and may be partially reversible.”2 ERS had defined COPD in 1995 as a 
disorder characterized by reduced maximum expiratory flow and slow 
forced emptying of the lungs, features which do not change markedly 
over several months.”3 But these definitions are not precise and may 
misdiagnose disease such as sarcoidos is cystic fibrosis, and 
bronchiectasis as COPD. More importantly44444 none of these 
definitions provide a clear cut difference between COPD and chronic 
asthma with airway remodeling. This is because, as mentioned by ATS, 
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some patients with COPD share some features of chronic ongoing asthma 
that make it difficult to differentiate the two. 
 
Global initiative for Chronic Obstructive Lung Disease (GOLD) 
was launched in 2001, which put forward definition for COPD which was 
revised in 2006, 2011, 2015. GOLD 2015 describes “COPD as a common 
preventable and treatable disease, characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious 
particles or gases.”1 Eventhough previous definition had stressed on terms 
emphysema and chronic bronchitis it had not been included in the current 
or earlier GOLD reports. In the previous definitions to make a diagnosis 
of COPD history of exposure to risk factors were not mandatory , but 
newer  definitions clearly stresses on the history of exposure to risk 
factors to make a diagnosis.  
Frequently the following components are considered while 
defining COPD: 
1) Measure of airflow limitation and reversibility  
Airflow limitation which is defined as a reduction in the velocity of 
expired air, incorporates a low FEV1 and a low FEV1 / FVC ratio post 
bronchodilator therapy. An FEV1/FVC ratio less than 70% has been used 
to make a diagnosis of COPD4,5. “Airflow reversibility is defined as an 
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increase in FEV1 by 200 ml and 12 from the baseline value in response to 
inhaled bronchodilators”. The reversibility of airflow obstruction 
following inhalation of bronchodilator or to oral or inhaled corticosteroid 
had been frequently use to identify the patients who would benefit from 
bronchodilator therapy. The use of airflow reversibility neither increases 
the sensitivity or specificity of diagnosingCOPD6 and the recent GOLD 
guidelines does not recommend the use of airflow reversibility for 
defining COPD. 
2) Clinical features and overlap syndromes: 
COPD includes chronic bronchitis and emphysema. Although 
significant advances in imaging fields helps in accurate diagnosis of 
emphysema, there exist significant variation in the physician diagnosis of 
both entities. As a result GOLD does not include these terms in definition 
of COPD.  
          Asthma is characterized by chronic airway inflammation and this 
leads to hyper responsiveness of airway which results in repeated attacks 
of wheezing, dyspnea, cough particularly at night or early hours of 
morning. These episodes have also been associated with widespread but 
variable airflow limitation which normalizes by itself or following 
treatment. Thus Asthma and COPD represents two separate diseases 
which have altogether different risk factors and pathogenesis, but the 
clinical features of the two may overlap which may lead to errors while 
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making a clinical diagnosis. But large population studies have found that 
a large proportion of the study candidates have been found to have more 
than one diagnosis (ie. Asthma and chronic bronchitis or emphysema7,8  
and this overlapping diagnosis are more common in elderly more than 
50years and the probability increases with age. 
 
EPIDEMIOLOGY 
Global scenario 
COPD represents one of the most prevalent diseases in the world. 
More than 210 million people have been affected globally. At present, 
COPD is the fourth most common cause of death worldwide, WHO has 
predicted that by 2030 it will be the third most common cause. 
Prevalence estimates of COPD depends on the criteria that is used for 
diagnosis. Until now, only a few studies have been able to provide a true 
estimate based on the standard spirometry definition. Even in United 
States studies were faced with major limitations which being firstly 
highly relying on the study participants and health care providers for 
proper recognition and diagnosis and secondly, they lack spirometry data 
to corroborate the evidence of airflow limitation. The study conducted by 
CDC in 2011 found that the prevalence was approximately 15 million in 
United States and it increased from 3.6 % among those less than 44 years 
to 11.6 % among those greater than 65 years. The overall prevalence of 
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COPD of GOLD stage II or higher was found to be 10.1 per cent and the 
prevalence in men accounted for 11.8 per cent  and in women  8.5 per 
cent9 was concluded from The Burden of Obstructive Lung Disease 
(BOLD) study from 12 sites involving 9425 subjects. The incidence of 
COPD varies greatly between countries, since they are reported in 
different units and over different lengths of time is difficult to do a 
comparison between the different studies that have been reported. In 
general incidence is greater in older people, particularly those aged 75 
years and above. Studies done in Canada and USA have reported that 
trends in incidence were similar between men and women over time10,11. 
But in Australia it was found that incidence decreased among men and 
increased in women12. India and China accounts for a majority of COPD 
mortality and it has been found  to be one among the highest in theworld. 
As per WHO Global Infobase it includes amongst both sexes more than 
64.7 estimated age standardized death rate per 100,000 . From this data it 
can be inferred that, the annual number of cases in India to be 
approximately 556,000 (20%)13 
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“COPD mortality projection: Global Burden of Disease Data 
Updated 20th January 2011” 
Indian Scenario 
The earliest study to know the prevalence of COPD in India was 
carried in rural Delhi by out by Wig et al in 196414. This study found a 
male preponderance of the disease with a prevalence of 3.36 % in males 
and 2.54% in females. In 1993, Jindal reported that the prevalence to be 
6.2% in men and that in women as 3.9% in rural area, and in urban area it 
was 4.2 and 1.6 per cent, respectively15. All these study groups 
represented the population from north India and so the information 
regarding the prevalence from South India was meagre. Thiruvengadam 
et al in 1977 from Madras (south India) reported the prevalence of COPD 
of 1.9 per cent in males and 1.2 per cent in females16 .Ray et al in 
199517from south India found that the prevalence was 4.08 per cent in 
 males and 2.55 per cent in females.
Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults 
(INSEARECH) conducted a study
85105 men, 84470 women from both urban and rural areas
showed that the overall prevalence of chronic bronchitis in adults >35 
year was 3.49 per cent (ranging 1.1% in Mumbai to 10% in 
Thiruvananthapuram).  The national burden of chro
estimated as 14.84 million based on this study
have 3 times higher risk of  developing COPD when compared to non
smokers and Bidi smokers were compared with their Cigarette smoking 
counterparts , the former was at 
.When the prevalence was compared with regard to cooking fu
exposure, it was 2% for those using LPG to about
Kerosene and/or biomass fuels or firewood. 
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 The Indian Study on Epidemiology of 
 around 2004-2006  involving a
nic bronchitis was 
. Smokers were found to 
a higher risk( 8.2%) than latter (5.9%) 
 5% among those using 
 
 total of 
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 “Estimated economic burden of COPD in India as 
 
According to the
Health (NCMH), which was set up in 2001 to study the burden of various 
diseases over the health care system of India, there were around 17 
million COPD patients in 2006 and it is estimated to 
around 201619. The current economic burden of COPD is 35,
Rs, and it is estimated to rise to a staggering 48,
years19 
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per current practice” 
 National Commission on Macroeconomics and 
reach 22 million by 
000 Crore Rs over next 5 
 
 
000 crore 
 “Estimated number of cases of COPD in India in the current decade
Causes of poor recgnition of COPD 
1. Underdiagnosis and under 
• Nonspecific symptomatology
• Absence of awareness of a definite diagnosis 
terminology
• Poor appreciation of symptom severity
• Non-availability or non
• Slow progression
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- burden and other pitfalls
assessment of COPD 
 
 
 
-use of spirometry 
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– overlap of 
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2. Lack of statistical information 
• Inadequate epidemiological data 
• Poor hospital records 
• Poor recognition of mortality data 
• Absence of burden assessment studies 
3. Pitfalls of management 
• Nonspecific management 
• Absence of guideline directed treatment 
• Inadequate preventive measures 
 
“RISK FACTORS FOR DEVELOPMENT OF COPD” 
  Host based Environmental 
Genetic factors Smoking 
Asthma/ airway hyperreactivity Occupational exposure 
 
Air pollution 
 
Childhood respiratory infections 
 
Low socioeconomic status 
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1. Genetic factors 
 “Alpha-1 Antitrypsin deficiency” 
Alpha-1 antitrypsin, is encoded by the SERPINA1 gene, which is a 
member of the serpine protease inhibitor superfamily (SERPIN).The 
major site of production of AAT is in the liver and it sub serves as  the 
major physiologic inhibitor of the serine protease neutrophil elastase. It 
also inhibits other serine proteinases including proteinase 3 (PR3) 
(Esnault et al,1993) and cathepsin G (Topic et al, 2009). The deficiency 
of AAT was first described in 1964 in two patients with emphysema. 
 
There are many variants of the protease inhibitor (PI or 
SERPINA1) locus that encodes AAT - 
• M allele- Most common and  is associated with normal AAT levels 
•  S allele-Associated with slightly reduced AAT levels 
•  Z allele- Associated with markedly reduced AAT levels 
• Null alleles- results in absence of any AAT production through a 
heterogeneous collection of mutations. 
 
“Most common form of genotype of severe AAT deficiency is 
individuals with two Z alleles or one Z andone null allele are referred to 
as PiZ and it is found only in 1% of patients with COPD”. It has also been 
found that there is a significant variability in the pulmonary function 
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among PiZ individuals, which is explained by cigarette smoking. There is 
an increased likelihood of early development of COPD among PiZ 
individuals with cigarette smoking. Asthma and male gender also 
increases the susceptibility of PiZ individuals to the development of 
COPD.  
       The risk of lung disease in heterozygous PiMZindividuals, those with 
intermediate serum levels of AAT (~60% of PiMM levels), is 
controversial. 
It has been found in several recent large studies that PiMZ subjects are at 
slightly increased risk for the development of airflow obstruction, but it 
unclear , whether other genetic or environmental factors contributes tothis 
increased incidence 
 
 Other genetic risk factors 
Recent Genome wide association studies (GWAS) have identified 
several susceptibility loci for COPD. These include  
• A region near the hedgehog interacting protein (HHIP) gene on 
chromosome4,  
• A cluster of genes on chromosome 15 (including component of the 
nicotinic acetylcholine receptor) 
• A region within a gene of unknown function (FAM13A regulatory 
SNP upstream from the HHIP gene 
 “Various newer genes involved in 
 
2. Airway hyperresponsiveness(AHR)
“It refers to the acute decline in maximal airflow on inhaling 
potential bronchoconstricting agents such as methacholine or histamine.
The AHR in COPD is associated with an accelerated decline in 
therefore considere
features and the pathogenic role of AHR is unclear, but it has been found 
that smoking cessation is associated with reduction in AHR
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pathogenesis of COPD
 
d to be a bad prognostic marker. The mechanistic 
” 
” 
FEV1 and 
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Environmental risk factors 
1. Cigarette Smoking 
Cigarette smoking is found to be the major contributing factor 
leading to mortality from chronic bronchitis and emphysema. There is a 
dose-response relationship between the accelerated decline in FEV1 and 
the intensity of cigarette smoking as shown by several longitudinal 
studies. As there is a dose-response relationship between reduced 
pulmonary function and cigarette smoking intensity, the prevalence of 
COPD increases with age. In the past there was a higher rate of smoking 
among male resulting in a higher disease prevalence among them, but in 
the present scenario, as the gender gap has diminished in smoking more 
disease is being reported among females.“Even though the best predictor 
of FEV1 is pack years of smoking, only 15% variability in FEV1 could be 
explained by no of pack years”. This suggests that environmental and 
genetic factors also adds to the impact of smoking in the development of 
airflow obstruction. Cigar and pipe smoking may also be associated with 
COPD, but the evidences relating to the development of disease is not so 
strong. 
 
 
 Proportional decline in FEV
2. Occupational exposure
The exposure to dust and fumes at work like 
mining, and cotto
obstruction and increased respiratory symptoms. The role of dust 
exposure, in the absence of cigarette smoking as a risk factor for COPD is 
not certain.  
 
3. Air pollution 
Since some studies have repor
COPD in urban areas compared to rural, the increased air pollution in 
urban areas has been related to this association. In some countries the 
19 
 
 
1 with increase in pack years
 
coal mining, gold 
n textile dust, have been associated with airflow 
ted an increased prevalence of 
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major risk factor for COPD among women is prolonged exposure to 
smoke produced by combustion of biomass which is used as a major 
source of fuel for cooking. Passive smoke exposure has been associated 
with a reduction in pulmonary function, the role in its development of 
severe airflow limitation in COPD is not certain. 
 
4. Respiratory infections 
The role of both adult and childhood respiratory infections in 
development and progression of COPD is yetto be proven. But infections 
are a major cause for exacerbation in COPD 
 
PATHOGENESIS 
 
• Inflammation and extracellular matrix proteolysis 
 
Macrophages and epithelial cells lining the alveoli become 
activated, on exposure to the oxidants in cigarette smoke which lead to 
production of proteinases and chemokines such as matrix 
metalloproteinases, proinflammatory cytokins such as interleukin 8 (IL-
8), and tumor necrosis factor α (TNF-α);this leads to neutrophil 
recruitment. CD8+ T cells release interferon-inducible protein-10 (IP-10, 
CXCL7), which triggers the macrophage to produce macrophage elastase 
(matrix metalloproteinase-12 [MMP-12]). Matrix metalloproteinases and 
serine proteinases, lead to lung destruction. It has been postulated that 
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autoimmunity also play a role in promoting the progression of the disease 
as evidenced by the presence of increased B cells and lymphoid follicles 
in patients with advanced disease.  
 
• Cell Death 
Oxidant present in cigarette smoke lead to structural cell death by 
inhibition of mammalian target of rapamycin (mTOR), which results in 
cell death as well as inflammation and proteolysis. In normal lungs, 
macrophages uptake the apoptotic cells which results in production of 
growth factors which dampens inflammation,and promotes lung repair. 
Cigarette smoke limits repair by inhibiting the macrophage uptake of 
apoptotic cells.  
3. Ineffective repair 
Following sustaining an injury, the ability to repair the damaged 
alveoli by the adult lung appears limited.  
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SYSTEMIC INFLAMMATION IN COPD 
 
Evidences have shown that in COPD patients with severe disease 
and during exacerbations, there is a high degree of systemic inflammation 
which results in increased levels of circulating cytokines, acute phase 
reactants, chemokines, and abnormalities in various circulating cell 
lines.20,21 The site of origin of these systemic markers is still not certain. It 
can be result as a spillover from the inflammatory processes in the 
peripheral lung, can develop as a parallel abnormality or may be related 
to some of the comorbid conditions. These components of systemic 
inflammation may have a pathogenic role in various systemic 
manifestations of COPD and may also worsen the various associated 
comorbid diseases. It was found in a large population study that there is 2 
fold to 5 fold increase in risk of cardiovascular diseases, lung cancer, 
pneumonia and diabetes in those with systemic inflammation as is evident 
from a raised level of fibrinogen, serum C-reactive protein, and 
leucocytes22. In a study conducted by using six markers of inflammation 
namely CRP, fibrinogen, leucocytes, TNF-α, IL-6, CXCL 8 , it was found 
that around 70% had evidence of inflammation and persistent 
inflammation was found in 16%. Persistent inflammation is associated 
with frequent exacerbations, increased mortality, accelerated decline in 
lung function. 
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Acute Phase proteins 
 C- reactive protein 
CRP levels are elevated in COPD patients especially during 
exacerbations. CRP is produced by liver in response to IL-6, therefore it 
may be considered as a marker of inflammation. It has been found in 
longitudinal studies that, FEV1 is related to CRP levels but no association 
is seen with progressive decline in FEV123  . Regardless of the etiology of 
exacerbation CRP levels are elevated in both bacterial and viral infections 
and the presence of persistently elevated CRP levels even after two weeks 
indicate the likelihood of a recurrent exacerbation. 
 
 Fibrinogen 
In patients with frequent exacerbations of COPD plasma fibrinogen 
levels have been found to be elevated24,25and it has been correlated to low 
FEV1 and increased likelihood of hospital admission 
 Serum amyloid A (SAA) 
It is an acute phase reactant that is produced from liver as well as 
from inflamed tissue due to stimulation by proinflammatory cytokines. Its 
levels are elevated during exacerbations and the levels also correlate with 
the severity of exacerbations 
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 Surfactant protein-D( SP-D) 
It is a glycoprotein and is mainly synthesized by Clara cells and 
type 2 pneumocytes of alveoli. It forms a part of innate immune system. 
Even though the levels are found to be raised in smokers and COPD 
patients, the correlation with severity is poor26. It has a poor specificity as 
it is elevated in other respiratory diseases like pneumonia, pulmonary 
fibrosis and asthma. 
 
Cytokines. 
• Interleukin-6(IL-6)   
There is found to be a consistent elevation of IL-6 during 
exacerbations and it acts a stimulant for the production of circulating 
CRP and SAA.27 Evidences suggest that IL-6 may have role in causing 
weakness of skeletal muscles. 
 
• Plasma TNF-α 
The plasma levels of TNF-α and its soluble receptor (sTNFR75) is 
seen to be increased in patients with COPD and in patients with cachexia 
TNF-α is also released from circulating cells. There is also found to be a 
correlation between TNF-α and hypoxemia28 
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• Interleukin 1β 
An association between IL-1β and cachexia has been found in 
COPD patients. 
 
• Other cytokines 
Cytokines such as CXCL8 and other CXC chemokines play an 
important part in recruiting neutrophils and monocytes. CXCL 8 has been 
related to muscle weakness and is increased in COPD patients. 
 
PATHOLOGY 
The large airways, small airways (≤2 mm diameter), and alveoli 
are affected by exposure to cigarette smoke. Cough and sputum occur due 
to changes in large airways, while physiologic alterations are produced by 
changes in small airways and alveoli. Most persons with COPD have both 
emphysema and small airway pathology eventhough they do not appear 
to be related to each other mechanistically, and their relative 
contributions to pathogenesis vary from one person to another. 
 
• Large airway 
There is goblet cell metaplasia and mucus hypersecretion in large 
airways. The main stimuli are Neutrophil elastase, Lipopolysaccharides, 
IL-1β, TNF-α, cigarette smoke and oxidative stress29. Cigarette smoke 
extract have been found to act synergistically with LPS or TNF- α in the 
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induction of MUC5AC expression by the goblet cells which is essential 
for mucus production. Thus there appears to be a potential amplification 
of cigarette smoke and inflammatory stimuli30 .Epithelial lining of bronchi 
also undergo squamous metaplasia, thus increases the risk of 
carcinogenesis and disrupts mucociliary clearance 
 
• Small airways 
The peripheral airways (i. e bronchioles <2 mm in diameter) are 
the major site of increased resistance to airflow in individuals with 
COPD31,32. The major pathologic lesions include increased number of 
inflammatory cells and structural changes, such as epithelial goblet cell 
metaplasia replacing surfactant secreting Clara cells, airway wall fibrosis, 
and smooth muscle hypertrophy33,34,35. The decrease in surfactant 
concentration may increase surface tension at the air-tissue interface, 
which further lead to airway narrowing or collapse. Narrowing and drop-
out of small airways is the pre runner of emphysematous destruction. 
 
• Lung parenchyma 
There is destruction of gas-exchanging airspaces, which includes 
the respiratory bronchioles, alveolar ducts, and finally alveoli. The walls 
of small distinct air spaces become obliterated and coalescence into 
abnormal and much larger air spaces. In all young smokers macrophages 
accumulate in respiratory bronchioles and analysis of bronchoalveolar 
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lavage fluid reveals roughly five times as many macrophages as that from 
nonsmokers. Among the major pathologic types of emphysema, the most 
important are centriacinar and panacinar. Centriacinar emphysema, is 
frequently associated with cigarette smoking, which is mostprominent in 
the upper lobes and superior segments of lower lobes. Panacinar 
emphysema usually occurs in patients with AAT deficiency and it has a 
predilection for the lower lobes. 
 
PATHOPHYSIOLOGY 
• Airflow obstruction 
Airflow limitation or airflow obstruction, is measured by 
spirometry,in patient has to perform expiratory maneuversafter inhaling 
to total lung capacity. Spirometry measures (FEV1) which is the volume 
of air exhaled withinthe first second of the forced expiratory maneuver 
and forced vital capacity [FVC] defined as thetotal volume of air exhaled 
during the entire spirometric maneuver. Ratio of FEV1/FVC will be 
reduced in patients with COPD. Unlike asthma, the reduction in FEV1 in 
COPD seldom shows reversal with inhaled bronchodilators, although 
improvements up to 15% are common. In both normal lungs and in lungs 
affected by COPD, towards the end of expiration the airflow diminishes 
because the resistance to airflow increases as both cross-sectional area of 
the airways and elastic recoil of lung falls. This decrease in flow 
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corresponds with decreased lung volume is evident on the expiratory limb 
of a flow-volume curve. In the initialstages of COPD, the abnormality in 
airflow becomes apparent at lung volumes equal or less than the 
functional residual capacity which becomes visible in the flow-volume 
curve as a scooped-out lower part of the descending limb. The entire 
curve has decreased expiratory flow in more advanced stages of disease. 
 
• Hyper inflation 
Both “air trapping” and progressive hyperinflation are seen in 
advanced stage of the disease. Hyperinflation preserves the maximum 
expiratory airflow, because increase in lung volume leads to increase in 
elastic recoil pressure and this leads to decrease in airway resistance. 
Hyperinflation pushes the diaphragm into a flattened position which 
results in a number of adverse effects; 
1) There is a decrease in the zone of apposition between the 
diaphragm and the abdominal wall, so the positive abdominal pressure 
created during inspiration is not applied to the chest wall. This hinders the 
movement of ribcage and impairs inspiration.  
2) The pressure generated during inspiration are lesser than normal 
because of shortened muscle fibers of the flattened diaphragm as 
compared to that of normally curved diaphragm 
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3) The flattened diaphragm have an increasedradius of curvature, 
(r) and according to Laplace’s law,  
p = 2t/r 
and to produce adequate transpulmonary pressure (p) required for 
tidal breathing it  must generate a greater tension (t). 
 
• Gas  Exchange 
Due to regional differences in compliance and resistance in 
airways, rates of ventilation differ in multiple parenchymal 
compartments. Reduction in Pao2 is mainly due to ventilation-perfusion 
mismatch and shuntingis minimal. So the hypoxia in COPD can be 
treated by modest amount of inspired oxygen and if hypoxemia is 
difficult to correct, then other complications should be sought for. 
 
Natural history of COPD 
The present day understanding of the natural history of COPD is 
from the seminal studies of Fletcher and coworkers36in the 1970s.The 
intensity of smoking exposure, exposure during growth, the baseline lung 
function of the individual, the timing of smoking, affect the decline in 
lung function. In most of the individuals pulmonary function increases 
with increasing age in childhood and adolescence, and declines gradually 
in old age. Reduced levels of FEV1 closely correlates with mortality in 
COPD. This rate of decline in pulmonary function can be modified by 
 changing the risk factors. Cessation of smoking after marked decline in 
pulmonary function have not pro
compared to smoking cessation atan earlier age. Genetic factors affect not 
only the  level of pulmonary function achieved during growth but also 
the rate of decline which occurs  in response to smoking and exposure 
other environmental factors.
"Hypothetical tracking curves of forced expiratory
(FEV1) for individuals throughout their life spans.
 
“The normal pattern of growth and decline with age is shown by 
curve A. Significantly reduced FEV1 (<
can develop from a normal rate of decline after a reduced pulmonary 
function growth phase (curve 
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decline after normal growth (curve B), or accelerated decline after normal 
growth (curve D).” 
Symptoms 
The clinical presentation of COPD is heterogeneous. It can be 
asymptomatic in those with mild disease to severe wheeze, cough, and 
sputum production as the disease progresses. Initially dyspnea may be 
present only on exertion and as the disease progresses it increase in 
severity and patients may modify their activities to avoid becoming 
breathless and so they may not be aware of the actual severity of the 
airflow limitation. Even though the dyspnea in COPD is multifactorial a 
significant role is played by exercise-induced air trapping also known as 
“dynamic hyperinflation”. Cough and sputum production in COPD is 
often more variable than dyspnea, and result in significant impairment of 
impact quality of life37and the cough may paradoxically increase after 
smoking cessation38. Sputum, tends to be mucoid, clear to white in 
appearance, and with exacerbations it becomes purulent. “Exacerbations 
of COPD are characterized by a sustained worsening of respiratory 
symptoms from the usual stable state beyond normal day to day 
variations”39 .Presence of bronchiectasis is indicated by excessive sputum 
production (more than 2 to 3 tablespoons daily) and the prevalence of 
which has been reported to be between 29% and 52% in moderate to 
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severe COPD and it results in increased mortality40. Hemoptysis may be 
seen in both chronic bronchitis and bronchiectasis but it should also raise 
the concern of development of lung cancer for which COPD patients are 
at increased risk41. 
 
Physical Findings 
In the early stages, no physical findings may be evident. Presence 
or absence of wheeze does not correlate with the severity of airflow 
limitation. Prolongation of expiration is more consistent finding, 
especially when disease progresses. FEV1/forced vital capacity(FVC) 
ratio of less than 50% to 60% corresponds to a forced expiratory time of 
more than 6 seconds42,43  . Signs of hyperinflation include a barrel-shaped 
chest, decreased breath sounds, muffled heart sounds, and increased 
resonance to percussion. Patients may breathe in a “tripod” position 
which takes advantage of the accessory muscles of the neck and upper 
chest and increase air movement. In severe disease patients may use 
pursed-lip breathing which creates back-pressure and it is also thought to 
reduce the dynamic hyperinflation and reduces bronchoconstriction44 
Systemic manifestations may be present in severe disease which include 
features of corpulmonale, and an accentuated pulmonic component of the 
second heart sound. Clubbing is unlikely in COPD and if present should 
arise the suspicion of malignancy and other comorbidities. Two 
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commonly recognized clinical subtypes of COPD are “blue bloaters” and 
“pink puffers”. Pink puffers, are associated with significant emphysema, 
compensate by hyper ventilation and have muscle wasting and weight 
loss. Blue bloaters have chronic bronchitis and they have less ventilation 
and a significant ventilation perfusion mismatch than emphysema and 
hence appear cyanotic, develop corpulmonale and appear “bloated”. 
 
 Pulmonary Function testing and diagnosis 
1) Spirometry 
Spirometry is considered as the gold standard for the diagnosis of 
COPD45,46. It plays a significant role in staging and monitoring of COPD. 
It helps to differentiate between respiratory diseases and other conditions 
that presents with similar symptoms. Spirometry as a tool for diagnosis of 
COPD is often underused. Epidemiological studies have thrown light into 
the fact that COPD will be under diagnosed in those with the disease and 
over diagnosed in those without the disease when spirometry is not used47   
Components of spirometry are: 
a) Forced vital capacity (FVC) 
b) Forced Expiratory volume in 1 second(FEV1) 
c) FEV1/FVC ratio 
The patient is asked to perform the “Forced exhalation maneuver”, 
in which patient inhales maximum as possible and exhales as fast as they 
34 
 
 
 
can. The amount of air the patient exhales in one breath is measured 
which is known as FVC and the amount of air the patient exhales in the 
first second is also quantified which is FEV1. 
FVC gives the measure of the amount of air the lung can hold and 
FEV1 is the measure of the ease with which the air flows in the lungs. 
Both FVC and FEV1 are expressed as percentage of the predicted value 
for the particular patient. The percent predicted is calculated based on the 
reference values that are calculated taking into consideration the age, 
gender and race of the patient. The inflammation of airways in COPD 
leads to narrowing which hinders the fast movement of air during 
expiration. This in turn leads to a decrease in FEV1. To make a diagnosis 
of COPD, FEV1 should be disproportionately decreased compared to 
FVC for which FEV1/FVC ratio is calculated. 
          The Gold Initiative for Lung Diseases, the combined American 
College of Physicians, American college of chest physicians, American 
Thoracic society and The European Respiratory society COPD guidelines 
recommends a fixed cut off of FEV1/ FVC less than .70 for making a 
diagnosis of COPD. To aid in easy diagnosis of COPD, this criterion has 
been set regardless of the age and gender. But since FEV1/FVC declines 
normally with aging, setting this fixed cut-off leads to overdiagnosis of 
COPD in elderly48,49 and under diagnosis in adults50. Another alternative 
is to use the Lower limit of Normal(LLN) for the cut-off of FEV1/FVC, 
 which takes age, height and gender into consideration for each individual. 
Eventhough it minimizes age related changes in FEV
more difficult to pe
correlation with exacerbations and mortality than LLN
The advantage of spirometry is that it 
physician’s office easily and should be recommended in all patients
symptoms and risk factors suggestive of COPD
obstruction is indicated by t
spirometry usually a flow
plotted on the y-axis and volume on the x
COPD shows a concav
seen in the volume 
“Fig A shows concave flow volume loop; B shows prolonged 
expiration
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Severity of COPD graded based on FEV 1 percent predicted and it 
is used in GOLD and ATS/ERS recommendations. It is recommended to 
use post bronchodilator FEV 1 should be used to determine the stage of 
severity since it is more reproducible than the pre bronchodilator FEV152 . 
“GOLD Classification of Severity of Airflow Limitation in COPD, 
Based on Post-Bronchodilator FEV1” 
 
GOLD category Severity FEV1 % predicted 
1 Mild ≥80% 
2 Moderate 50%≤FEV1<80% 
3 Severe 30%≤FEV1<50% 
4 Very severe <30% 
 
 
Some patients may have difficulty in performing a forced 
exhalation maneuver due to poor mental status or coughing. The possible 
alternatives that have been suggested include slow vital capacity or FEV 
in 6 seconds (FEV6) in place of FVC and FEV1 /FEV6 ratio instead of 
FEV1/FVC ratio.53 
 
2) Lung volumes 
Total lung capacity (TLC) and Residual volume(RV) are measured 
via plethysmography in a typical pulmonary function laboratory. In  
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COPD, especially in emphysema TLC is increased due to lung 
hyperinflation as elastic recoil of lung is lost. Other lung volumes which 
may be increased are Residual volume (RV) and Functional residual 
capacity. Increase in RV is greater compared to TLC resulting in an 
increase in RV/TLC ratio. 
 
3) Diffusion Capacity 
       Diffusing capacity for carbon monoxide (DLCO) is an indirect 
measure of the alveolar capillary blood volume and is decreased in the 
presence of emphysema, and other diseases that affect capillary bed of 
alveoli such as pulmonary fibrosis. If a patient has almost normal 
spirometry and lung volumes and severely decreased diffusing capacity 
and X ray imaging corresponds to emphysema, then a diagnosis of 
combined pulmonary fibrosis emphysema syndrome should be 
considered.54  
 
4) Exercise testing 
         The 6-minute walk test(6MWT) is one of the most commonly used 
exercise test in COPD.6-minute walk distance (6MWD) is the distance a 
patient can walk in 6 minutes.55To perform this test, there is no need of 
any specialized equipment or any prior training. 6MWT helps the 
clinician to assess the adequacy of oxygenation during ambulation and 
also helps to decide regarding the need for supplemental oxygen. Patients 
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are also subjected to this test prior to lung transplantation to assess the 
functional status and to predict the prognosis. It is an indicator of 
mortality in COPD index and is one among the four components of 
BODE index. But to know the specific cause of dyspnea, a more formal 
cardiopulmonary exercise testing (CPET) should be performed using 
either a treadmill or cycle ergometer. Since most of the patients do not 
achieve maximal exercise capacity during the 6MWT, the result better 
correlates with functional exercise capacity56. It also correlates better with 
quality of life and the treatments which improve 6MWT also leads to 
decrease in the grades of dyspnea. CPET helps to measuremaximal 
oxygen uptake (_VO2), carbon dioxide output (_VCO2), maximal work 
rate, and anaerobic threshold. CPET is also an integral part in evaluation 
before a patient is subjected to lung volume reduction surgery (LVRS) 
because those who would benefit more from the surgery are those with a 
low work rate. 
 
5) Imaging 
Most commonly used imaging techniques being used in COPD are 
chest radiography and computed tomography(CT). Imaging is mainly 
used to rule out other disease with similar presentations and 
complications. Most commonly seen findings in Chest X-ray that may be 
attributed to COPD are Radiolucency, flattening of diaphragm, and in the 
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lateral radiograph there may be an increased retrosternal airspace in the 
presence of hyperinflation. Radiolucent areas may also indicate the 
presence of large bullae. 
Chest CT is better for detection as well as quantification of the 
disease57 compared to chest X-ray. It is a prerequisite for Lung volume 
reduction surgeries. Emphysema will be evident as low attenuation areas 
and bronchial thickening may also be seen. Expiratory films reveal small 
airway disease as well as air trapping. It also helps to rule out other 
respiratory diseases. Since COPD patients are also at an increased risk of 
lung cancer, it seems appropriate to screen individuals of age between 55 
to 74 years with a smoking history of 30 pack-year including the patients 
who had quit smoking in the past 15 years. 
 
4) Laboratory testing 
a) Arterial blood gas analysis(ABG) 
ABG is not a routine test in the evaluation of COPD patients as 
pulse oximetry is usually sufficient to assess the arterial blood oxygen 
saturation. ABGs are particularly useful in detecting hypoxemia and 
hypercapnia, especially during exacerbation or in individuals with severe 
disease. During exercise, there occurs further worsening of ABG 
abnormalities 58 Until the FEV1 to ~50% of predicted there won’t be any 
deviation of PaO2 from normal and an increase in  arterial level of carbon 
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dioxide (Paco2) is not usually seen unless FEV1  is <25% of predicted 
and even then it may not occur. FEV1 (<25% of predicted) and chronic 
hypoxemia (Pao2 <55 mmHg) can lead to pulmonary hypertension which 
may result in cor pulmonale and right ventricular failure. 
 
b) Erythrocytosis 
Chronic hypoxemia in COPD lead to erythrocytosis and increase in 
hemoglobin. It also helps to differentiate from other causes of dyspnea 
like anemia 
 
c) Serum bicarbonate levels 
In cases of chronic hypercapnia bicarbonate levels may be elevated 
to compensate for the respiratory acidosis 
 
5) Testing for Alpha1 antitrypsin deficiency 
According to ATS guidelines tests to detect AAT deficiency should 
be performed in all individuals with airflow obstruction that is persistent59  
 
AAT deficiency should be suspected when; 
• Emphysema occurs at a young age, 
• Emphysema occurs in an individual with minimal or no smoking 
history, 
• In presence of lower lobe predominant emphysema 
• In the presence of family history of emphysema 
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AAT deficiency may also occur in patientswith more typical 
COPD. The probability of AAT deficiency is increased with serum levels 
below 11micromol/L (approximately 50 mg/dL when using nephelometry 
(i.e., immunoturbidimetry) and 80 mg/dL in case of radial 
immunodiffusion). In case of positive blood test the diagnosis should be 
confirmed by performing genotyping. Those at high-risk of developing 
the disease are individuals with genotypes S, Z, and null alleles are the 
ones with maximum deficiency). In situations where there is a 
discordance between serum level and genotyping, protein phenotype 
analysis should be performed using electrophoresis in which alleles with 
abnormal protein migration patterns will become evident. 
 
6) Sputum examination 
There is no indication for routine sputum evaluation in for 
diagnosis and further care of the COPD patients. In stable patients, there 
is a predominance of macrophages and few bacteria the number of which 
increases during acute exacerbation. Haemophilus influenzae, 
Streptococcus pneumonia and Moraxella catarrhalis constitute the most 
common pathogens which are identified on sputum culture60 .Other 
organisms which occur less frequently are Pseudomonas aeruginosa, 
Staphylococcus aureus and other gram-negative rods. The causative role 
of the bacteria isolated from the sputum during acute exacerbations have 
 been questioned, as some longitudinal studies have shown that the 
probability of isolating bacteria during acute exacerbation is almost 
similar as that in stable state.
bacteria from sputum during stable COPD have been associated with 
more number of exacerbations 
function.  
 
ASSESSMENT OF SYMPTOMS
 Modified MRC dyspnea scale
In the past, as COPD was considered as a 
characterized by breathlessness, Modified British Medical Research 
Council (mMRC) Questionnaire was advocated widely for symptom 
assessment, as it correlated well other measures of health status
predicted the mortality 
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risk in future. But now as more light has been thrown into the 
systemic nature of COPD, more comprehensive tools for symptom 
assessment is required. 
 
 St. George Respiratory Questionnaire 
St. George Respiratory Questionnaire62 (SGRQ) is the most widely 
documented comprehensive measure and  is used to measure impairment 
of health in both asthma and COPD patients. As it is more longer its use 
is mainly limited to research settings. It consists of two parts: 
• Part 1(Questions 1 to 8): It produces the symptom score of the 
patient. It is mainly based on the patient’s recollection of their 
symptom profile which may range from one month to one year. 
So it is not considered to be accurate epidemiological tool. 
More recently a 3- month recall version has been validated and 
use satisfactorily. 
• Part 2(Questions 9 to 16): The activity and impact scores are 
derived from this part. It helps to know the current state of the 
patient. The Activity score gives a measure of the difficulty of 
the patient in carrying out activities of daily living. The Impact 
score addresses the psycho- social effect of the disease. Several 
validation studies have found that the Impact scores correlates 
well with respiratory symptoms. Stronger correlation was 
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found with breathlessness in daily life (mMRC dyspnea scale, 
Exercise performance(6-minute walking test) and disturbances 
in mood (anxiety and depression). Thus Impact score is 
considered to be the broadest component of SGRQ 
questionnaire. 
 
A total score is produced from Part 1 and Part 2. The questionnaire 
has been designed for supervised self-administration. So the patients 
should complete the questionnaire by themselves, but clarifications of 
questions can be given by an appropriate trained person. Based on the 
responses given by the patients the scores are calculated using excel 
based scoring calculator. The lowest possible score is zero and maximum 
is 100.  
 
 COPD Assessment Test(CAT) 
The COPD Assessment Test is an 8 item questionnaire which gives 
an unidimensional measure of impairment health status in COPD63. The 
score ranges from a minimum of 0 to a maximum of 40, and it has a good 
correlation with SGRQ scores. 
 
 COPD Control Questionnaire(CCQ) 
It is self- administered 10 item questionnaire which is used to 
measure the extent of clinical control achieved in patients with  
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COPD64 ,65. The advantage of CCQ is that its short and can be performed 
easily. However the use of the concept of “control” in COPD has led to 
controversy. 
 
Choice of cut off Points: 
The CAT and CCQ scores cannot be used as a guiding tool for the 
purpose of initiating treatment as they do not categorise the patients into 
those with higher and lower symptoms. SGRQ has got a wide 
documentation and is the most comprehensive measure. In patients who 
are already diagnosed SGRQ scores less than 25 are usually not seen66 
and scores ≥ 25 are also very unlikely in healthy persons66. In clinical 
trials using long acting bronchodilator medication, it was found that the 
baseline weighted mean score was 44 and one standard deviation below 
the mean was 2667,68 .So it has been recommended that the cut-point for 
starting regular treatment for symptoms is a symptom score equivalent to 
SGRQ score ≥ 25 which corresponds to a cut- off of 10 for CAT. CCQ 
equivalent scores have not yet been determined, but it appears to around 
1.0- 1.5. It is difficult to keep an equivalent mMRC score as cut- off 
because it does not correlate well with the SGRQ score. Since mMRC is 
used widely a score ≥2 has been included as a cut- point for separating 
“less breathlessness from more breathlessness”. As mMRC do not 
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consider symptoms other than breathlessness, it is prudent to assess other 
symptoms separately. 
 
SYSTEMIC MANIFESTATIONS AND COMORBIDITIES     
 
COPD has now been recognized as a disease which has an impact 
on various organ systems, the so called systemic effects and 
comorbidities of COPDBut it is not clear whether they are due to shared 
risk factors or COPD directly has a causative role. 
 
“Observed systemic effects and comorbidities of COPD” 
Systemic effects of COPD Comorbidities of COPD 
Muscle dysfunction Cardiovascular disease 
Cachexia Lung cancer 
Anemia Osteoporosis 
Muscle dysfunction Diabetes 
Autonomic dysfunction Psychological issues: 
anxiety/depression 
Systemic inflammation Obstructive sleep apnea 
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1) Cardiovascular disease 
Ischemic cardiovascular disease is undoubtedly the most leading 
cause of morbidity and mortality in COPD69. The common risk factor for 
this association is tobacco use but impaired lung function is postulated to 
act as an independent risk factor accounting for increased cardiovascular 
mortality even when after adjustments for smoking status. Among COPD 
patients FEV1 also act as a predictor for both atherosclerosis and 
cardiovascular mortality. The common link between COPD and 
atherosclerosis is systemic inflammation. This leads to increase in acute 
phase reactants and elevated levels of C-reactive protein levels correlates 
with both presence of COPD and also presence of exacerbations, as well 
as severity of disease, and risk for hospitalization and death70. Potential 
(NA) mechanisms for cardiovascular disease in COPD includes:  
 
• Systemic and lung inflammation 
• Both alveolar and tissue hypoxia 
• Hypercapnic acidosis 
• Endothelial/ vessel wall abnormalities 
• Polycythemia 
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2) Osteoporosis 
Studies have found that the prevalence of osteoporosis in COPD 
patients is two to five folds more as compared age matched controls71,72. 
The shared risk factors which influence thisassociations are use of inhaled 
and oral steroids cigarette smoking, and a lower body mass index. But 
this does not explain the presence of osteoporosis in patients who are not 
exposed to any systemic steroids. Pulmonary rehabilitation plays a 
significant role in improving the functional status and by decreasing the 
risk of falls, might diminish the risk of fracture. 
 
3) Diabetes 
Various studies have shown that the prevalence of diabetes in 
COPD is between 1% and 16%73. Even patients with mild disease have 
an increased risk of developing diabetes (risk ratio- 1.5-1.8). There has 
been found to be an association between decreased lung function and 
metabolic syndrome and also with insulin resistance and increased 
incidence of diabetes. A study by Poulain and colleagues have shown that 
the presence of abdominal obesity is associated with inflammatory and 
metabolic abnormalities and increased development of diabetes. They 
found that there is an increased level of TNF-α and IL-6 which may block 
the signaling in insulin receptors and result in insulin resistance. This 
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finding further strengthens the causative role of common inflammatory 
pathway in the systemic effects of COPD. 
 
4) Gastroesophageal reflux disease 
COPD has been found to be associated with increased prevalence 
of gastroesophageal reflux disease74 .The clinical implication of increased 
GERD is that it is associated with poor quality of life and frequent 
exacerbations75 It has also been observed that chronic bronchitis is 
associated with reflux than emphysema. The clear pathogenic mechanism 
between this association has not been elucidated. 
 
5) Anxiety and depression 
The prevalence psychological stress (anxiety, depression) has been 
estimated to be around 10% and it increases as the severity increases. The 
major risk factors include limitation of mobility, requirement of 
supplemental oxygen therapy, presence of other comorbidities, and 
female sex76. The patients with anxiety experience more frequent 
exacerbations and risk of death is also more in patients with depression 
 
6) Skeletal muscle dysfunction 
The prevalence of muscle wasting is estimated to be around 18-
36%. Inactivity appears to be the major causative factor as atrophy is 
more commonly found in relatively inactive muscles like quadriceps and 
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vastus lateralis77Other factors implicated in the pathogenesis are 
imbalance in protein synthesis and degradation, hypoxia oxidative stress, 
inflammation, dysfunction of mitochondria and apoptosis78. It has been 
found that quadriceps atrophy is associated with decreased exercise 
capacity, poor health status, increased dependence on health care 
resources, increased mortality that is independent of limitation of airflow. 
 
7) Anemia 
As with any other chronic, inflammatory, multisystem disease 
COPD is also found to be associated with anemia. Presence of anemia is 
an independent determinant for lower bone mineral density and elevated 
CRP levels as was found in the study by Rutten and colleagues. The 
presence of chronic inflammation also leads to resistance to 
erythropoietin. 
 
8) Lung cancer 
COPD is an independent risk factor for the development of lung 
cancer, and a patient with moderate to severe disease has almost 5- fold 
increased risk of lung cancer79. There exist an inverse correlation between 
risk of lung cancer and the degree of airflow limitation independent of 
exposure to cigarette smoke. Reduced FEV1 is the most important risk 
factor for the development of lung cancer after allowing for cigarette 
smoke exposure as shown by cross sectional studies. The pathogenenic 
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mechanisms linking the two diseases appear to be multifactorial among 
which major role is played by inflammation and oxidative stress. NF- κB 
is one of proposed link between lung cancer and COPD. Nuclear factor 
erythroid 2- related factor 2 (Nrf2) is involved in expression of 
detoxifying enzymes and acts as a major defense against various 
carcinogens in tobacco smoke. It’s down regulation is associated with 
increased susceptibility of COPD patients to lung cancer. 
 
9) “Obstructive sleep apnea and obesity in COPD” 
Physical inactivity has been proposed to be the risk factor for the 
development of obesity in COPD. Use of oral glucocorticoids also 
contribute to the development of truncal obesity due to the truncal 
redistribution of store energy. 20 % of the patients affected with OSA 
have been shown to have COPD in various epidemiological studies 
whereas independent of the severity 10% of those with COPD have OSA. 
The postulated mechanisms include alteration in nocturnal neuro 
hormonal secretion, elevated parasympathetic tone, bronchoconstriction 
or vasoconstriction caused by hypoxemia, stimulation of upper airway 
neural receptors. 
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BIOMARKERS IN COPD 
“A biomarker is a molecule, the measurement of which reflects the 
disease activity”. Promising biomarkers in blood that may be helpful in 
predicting mortality derived from large scale studies include: 
 
1) Fibrinogen 
Study by Danesh et al80 have found that an increase in the blood 
level of fibrinogen by 1g/L has been associated with an increase in 
mortality by about 3.5 fold 
 
2) C-Reactive protein 
Several studies have shown that increase in blood levels have been 
associated with increased death from respiratory failure and lung cancer 
but it has also been shown that CRP levels have not been consistently 
associated with increased frequency of exacerbations 
 
3) IL-6 
It is a better predictor of three year mortality compared to IL-6 and 
CRP in predicting 3- year mortality. The major disadvantage is the non 
repeatability of IL-6 over time. 
 
4) Bilirubin 
Serum bilirubin is an emerging biomarker in COPD. Bilirubin has 
an antioxidant action. Horsfall et al81showed in their study that there  
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is an inverse relation between COPD mortality and bilirubin levels. 
 
6) Pneumoproteins 
Since biomarkers commonly used(CRP, fibrinogen, IL-6) are not 
produced in the lungs, they lack specificity. To address this problem 
focus has been shifted to proteins produced or modified in lungs which 
are referred to as pneumoproteins. SP-D and CCSP-16(Clara cell 
secretory protein 16) are the two major proteins which are best studied to 
this date. There is no relation between SP-D levels and disease 
progression and severity they are associated with an increased frequency 
of exacerbation 
 
PROGNOSTIC FACTORS IN COPD 
There are a number of factors identified as prognostic indicators for 
COPD. Those which are associated with accelerated decline of lung 
function and increased mortality include82 
• “low FEV1 
• Airways  hyper responsiveness 
• History of Cigarette smoking 
• Decreased body-mass index (BMI ≤21) 
• Presence of HIV infection 
• Increase in bacterial load in airways 
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• Decrease in  exercise capacity 
• Peak oxygen consumption (VO 2 ), measured by cardiopulmonary 
exercise testing 
• C-reactive protein levels >3 mg/L 
• Male gender 
• Chest computed tomography showing presence of emphysema” 
Multidimensional scales 
1) BODE Index 
As it has been proved that COPD is a disease that is characterized 
by widespread systemic inflammation affecting various organ system, 
there is need for novel indices which also considers the systemic nature of 
the disease. FEV1aloneas used in GOLD staging is a good predictor of 
mortality but not of dyspnea and health status, number of exacerbations, 
hospitalizations82. In this context Celli et al(2004) developed the 
multidimensional BODE index which predicts not only risk of death but 
also the chance of hospitalization and correlates better with the health 
related quality of life of the patient. 
 
 
 
  
2) mBODE index 
The modified BODE (mBODE) index makes use of an alternate 
dyspnea questionnaire (ie, UCSD SOBQ) and 
predictor of mortality
3) Body mass Index
Body mass index (BMI)
in predicting prognosis in COPD. Low 
higher mortality84whereas 
4) Fat-free mass index (FFMI)
FFMI is a better indicator of increased mortality than 
Observational studies have shown that even though both FFMI and BMI 
relates well to 6- minute walk test, among the only FFMI has a better 
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The BODE Index 
it appears to be a better 
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 is found to be an independent risk factor 
body mass is associated with 
weight gain is found to improve the
 
 
 prognosis  
BMI85. 
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correlation with FEV 1 /FVC , the FEV 1, ratio degree of chronic dyspnea, 
or the stage of disease 
 
TREATMENT OF COPD 
 Stable COPD patients 
According to the available evidences, the only interventions that 
modify the natural course of COPD are cessation of smoking, Oxygen 
therapy in patients with chronic hypoxemia and lung volume reduction 
surgeries. Glucocorticoids may have a role in altering the mortality rate. 
All other treatments available mainly aim to improve the severity of 
symptoms, to decrease the frequency as well as morbidity associated with 
exacerabtions. 
 
1) Pharmacotherapy 
• Cessation of smoking 
All COPD patients should be educated regarding the benefits of 
smoking cessation, and be encouraged for quitting. The pharmacological 
agents available include, replacement therapy for nicotine which is 
available as gum lozenge patch, nasal spray, and inhaler; bupropion; and 
varenicline, which acts as a agonist/antagonist of nicotinic acid receptor. 
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• Anticholinergics 
Ipratropium and tiotropium are the two agents which are 
commonly used. Ipratropium being short acting produces a rapid 
improvements during acute exacerbations, whereas, Tiotropium being 
long acting, reduces exacerbations and improves symptoms. But neither 
of the two has any influence over the rate of decline of FEV1. 
 
• Beta agonists 
Long acting Beta agonists like Formoterol and salmeterol have 
effects comparable to anticholinergics and has synergistic actions when 
compared with them. 
 
• Inhaled Glucocorticoids 
The effect of IGCS in reducing the mortality in COPD patients is 
controversial. From the available data it has been concluded that IGCS 
lead to 25% reduction in exacerbation frequency. So it is prudent to 
consider a trial of IGCS in patients with frequent exacerbations and 
patients with a demonstrable acute reversibility in response to IGCS. 
 
• Oral steroids 
It is not recommended to use chronic oral steroids because of the 
increased adverse events than benefits associated with them. 
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• Theophylline 
 In patients with moderate to severe disease its use is associated 
with improvement in hypoxemia and hypercapnia as well as expiratory 
flow rates. But monitoring of blood levels are required to decrease 
toxicity. The use of selective PDE-4 inhibitor Roflumilast reduces the 
frequency of exacerbations. 
 
• Antibiotics 
As bacterial infections are the major cause of exacerbations, trials 
administering antibiotics round the year or seasonally were conducted. 
But it failed to show any benefit. Recently trials have shown that daily 
administration of azithromycin in patients with frequent exacerbations, 
have reduced the frequency of exacerbations. This has been attributed to 
both antimicrobial and the anti-inflammatory action of azithromycin. 
 
• Supplemental oxygen 
It has been shown that oxygen therapy decreases mortality in 
patients with a resting hypoxia as evidenced by saturation less than ≤88% 
or <90% with evidence of right heart failure or pulmonary hypertension. 
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2) Non pharmacological measures. 
• Vaccinations  
All COPD patient should receive influenza vaccine annually, 
Polyvalent pneumococcal vaccine. 
 
• Pulmonary rehabilitation 
It involves educating the patient about the nature of the disease and 
cardiovascular condition. It has been proven that pulmonary rehabilitation 
leads to improvement in dyspnea, health related quality of life, increase in 
exercise capacity and decrease in hospital admission.  
 
• Lung volume reduction surgery 
The National Emphysema Treatment trial have shown that LVRS 
is associated with both a mortality and symptomatic benefit in the 
selected patients. The major indications are severe dyspnea that are not 
amenable to medical therapy or pulmonary rehabilitation86, FEV1 less 
than 45% of predicted, DLCO ≥ 20% of predicted, six-minute walk 
distance greater than 140 meters, post rehabilitation, Evidence of air 
trapping in lung volume measurements , age < 75 years. The exclusion 
criteria include presence of pulmonary artery systolic pressure exceeding 
45 mm Hg, severe pleural disease, congestive heart failure, FEV1< 20%, 
DLCO <20%, presence of diffuse disease 
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• Lung transplantation 
“COPD is the second major indication for lung transplantation.”  
According to current recommendations lung transplantation should be 
done in patients with severe disability even after instituting the maximal 
medical therapy. The patients should free from other comorbid diseases 
involving liver, heart and kidneys 
 
 Acute Exacerbations 
Exacerbations in COPD are defined as episodes of increased 
dyspnea and cough a and change in the character and amount of sputum 
production which may or may not be associated with fever, sorethroat or 
myalgia87,88.Frequency of exacerbations correlate better with health-
related quality of life than does degree of airflow limitation. The trigger 
for exacerbations include respiratory infections, acquisition of a new 
strain of bacteria in patients with chronic colonization89, exposure to air 
pollulants. The goal of treatment minimize the impact of exacerbation 
over quality of life, decrease the decline in lung function, and prevention 
of subsequent exacerbations. The major indications for hospitalization 
include, severe underlying disease, dyspnea of higher grade or respiratory 
insufficiency, presence of other comorbidities, frequent exacerbations, 
elderly patients, and poor support at home. Treatment of exacerbations 
include use of : 
 • Bronchodilators
muscarinic antagonists
• Corticosteroids
prednisolone per day for 2 weeks, however recent trials have 
shown similar benefit with 40 mg of oral prednisolone for 5 days
• Antibiotics- H. influenzae, S. pneumoniae, and M. catarrhalis cause 
nearly 50% of the acute exacerbations.
it is advisable to start empirical antibiotic treatment when there is 
increased likelihood of infection for a duration of 
• Mechanical ventilation
“Indications for Mechanical ventilation in acute exacerbations
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- should be used alone or in combination with
90
. 
- The recommended dose of steroids is 40
According to the guidelines 
5 to 10 days.
 
 
- 60 mg of 
91
 
 
 
” 
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MATERIALS AND METHODS 
SELECTION OF VOLUNTEERS 
Already diagnosed stable COPD patients attending the Thoracic 
Medicine OPD –Rajiv Gandhi Government General Hospital from April 
2025 –September 2015 are selected according to the inclusion criteria. 
 
STUDY CENTRE 
Thoracic Medicine outpatient department, Rajiv Gandhi 
Government General Hospital 
 
DURATION OF STUDY 
6 months 
 
STUDY DESIGN 
Observational study 
 
SAMPLE SIZE 
50 patients 
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INCLUSION CRITERIA 
• COPD patients in stable conditions with no exacerbations due to 
any reason in the last 6 weeks). COPD is defined as a history of 
smoking and an FEV1/FVC ratio of less than 70% , 20 minutes 
after salbutamol administration 
EXCLUSION CRITERIA 
Patients with history of: 
•  Inflammatory diseases (inflammatory bowel disease, 
rheumatologic diseases, vasculitis),  
• Interstitial lung diseases, or presence of active tuberculosis 
• Presence of atopy, 
• Myocardial infarction in the last 6 months,  
• Decompensated cardiovascular disease and 
• Walking disability. 
STATISTICAL METHODS 
The analysis was done using statistical software SPSS 20.0.The 
statistical analysis within the study was done using one way ANOVA 
test, t test. 
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DATA COLLECTION AND METHODS 
From COPD patients attending the Thoracic medicine department 
OPD, selected for clinical study as per inclusion/exclusion criteria the 
following data are collected: Demographic data, Past medical history. 
Weight, height are measured. Dyspnea severity is assigned by MMRC 
dyspnea scale. Patients are subjected to the six-minute walking test 
(6MWT), Spirometry is done. Blood is drawn for estimation of  
C- reactive protein. Patients are requested to fill up the vernacular version 
of St George respiratory disease questionnaire to assess the quality of life. 
Detailed clinical examination is done. BODE index is calculated from 
BMI, FEV1, 6- minute walking distance, MMRC dyspnea scale.  FEV1 
(expressed as percentage of predicted) is used for GOLD staging. BODE 
index and Gold staging are correlated with CRP levels, SGRQ total score 
and prognostic factors. 
SPONSORSHIP  
No 
CONFLICT OF INTEREST 
None 
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OBSERVATION AND RESULTS 
Table no 1Total number of cases 
Sex Frequency Percent 
Male 44 88.0 
Female 6 12.0 
Total 50 100.0 
In the study group of 50 patients, 44 patients were male and  
6 patients were female 
 
 
 
Total number of cases
Males Females
 Table no: 2
Age group 
51-55 
56-60 
61-65 
66-70 
71-74 
In the study group, 
61-65 yrs 
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 Age group distribution 
Total Percentage
6 
14 
16 
13 
1 
the maximum incidence was in the age group of 
 
56-60 61-65 66-70
Age group distribution
 
12 
28 
32 
26 
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71-74
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Table no: 3 Baseline demographic characteristics of the population 
Variables N Minimu
m 
Maximu
m 
Mean Std. Deviation 
Age in years 50 52 70 62.16 5.052 
Pack Years 44 14 30 22.43 3.979 
Duration of illness 50 3 7 4.92 1.066 
No of Annual 
Exacerbation 50 1 6 3.40 1.143 
No of Hospitalisation 
in previous year 50 0 5 1.88 1.043 
Serum CRP Level 
(Mg/L) 50 4.50 26.70 14.1714 4.34393 
FEV1 (L) 50 .85 1.64 1.2976 .19494 
Post bronchodilator 
FEV1 % 50 40 71 55.53 6.409 
FVC (L) 50 1.71 3.10 2.5806 .35032 
Height (Cms) 50 150 170 160.90 5.136 
Weight   ( Kgs) 50 45 65 52.70 4.156 
Body Mass Index 50 18.14 30.31 20.5536 1.85211 
6 Minute Walking 
Distance (M) 50 120 380 221.80 57.310 
MMRC Dyspnoea 
Grade 50 1 3 2.36 .663 
Bode Index Scores 50 0 8 4.82 1.711 
SGRQ - Symptoms 50 32.85 95.71 68.1874 13.56043 
SGRQ - Activity 50 41.73 92.51 68.5668 11.04639 
SGRQ - Impact 50 20.75 91.94 63.6762 14.86575 
SGRQ - Total 50 29.90 92.74 65.8348 12.62675 
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Analysis of Basic demographic data: 
Mean age of the study group was 62.16 years with minimum of 50 
years and a maximum of 70 years. Cumulative smoking pack years was 
22.43 with a minimum of 14 and maximum of 30. The mean Body mass 
index was 20.55kg/m2. Mean 6-MWD was 221.80 m and post 
bronchodilator FEV1 % was 55.53%. The mean SGRQ scores for 
symptom: 68.18, activity: 68.56, impact: 63.67 and total: 65.83. the mean 
BODE index score was 4.82 
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Table no 4: Distribution of SGRQ scores according to GOLD stages 
 Gold Stage N Mean Std. Deviation 
Std. 
Error 
Mean 
 
P value 
SGRQ - 
Symptoms 2 42 66.2836 13.19812 2.03651 
 
<.05* 
 3 8 78.1825 11.44631 4.04688  
SGRQ – 
Activity 2 42 65.5686 8.85070 1.36569  
 3 8 84.3075 7.63144 2.69812 <.001** 
SGRQ - 
Impact 2 42 60.4983 13.46555 2.07778  
 3 8 80.3600 10.30560 3.64358 <.001** 
SGRQ – 
Total 2 42 62.9138 11.20287 1.72864  
 3 8 81.1700 7.80972 2.76115 <.001** 
 
In the study group, 42 patients had a GOLD stage of 2 and 8 had a 
GOLD stage of 3. Mean total SGRQ scores increased according to GOLD 
classes. There was highly significant correlation between SGRQ scores 
for activity impact and the total scores (p value<.001**) whereas there 
was still a significant correlation between SGRQ symptom score and 
GOLD stages(p value<.05). So SQRQ activity and impact score 
correlated better with GOLD stages than SGRQ symptom score. 
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Table no : 5 Comparison of SGRQ symptom score and BODE index 
 
Bode 
index 
quartile
s 
N Mean Std. Deviation 
Std. 
Error 
95% Confidence Interval 
for Mean 
 
P value 
     
Lower 
Bound 
Upper 
Bound 
 
 
 
<.001** 
0-2 5 38.5220 3.76376 1.68321 33.8487 43.1953 
3-4 14 61.2093 5.78421 1.54590 57.8696 64.5490 
5-6 25 74.5624 5.50932 1.10186 72.2883 76.8365 
7-10 6 82.6283 9.39312 3.83473 72.7709 92.4858 
Total 50 68.1874 13.56043 1.91773 64.3336 72.0412  
 
 
Table no: 5 Comparison between SGRQ activity score  
and BODE index 
Bode 
index 
scores N 
Mean 
activity 
score 
Std. 
Deviation Std. Error 
95% Confidence Interval 
for Mean 
 
     
Lower 
Bound Upper Bound 
P value 
0-2 5 52.0440 9.43855 4.22105 40.3245 63.7635  
3-4 14 61.4971 6.19776 1.65642 57.9187 65.0756 <.001** 
5-6 25 71.9212 6.38655 1.27731 69.2850 74.5574  
7-10 6 84.8550 6.42852 2.62443 78.1087 91.6013  
Total 50 68.5668 11.04639 1.56220 65.4275 71.7061  
 
 
In the study group, SGRQ symptom and activity score increases 
with increase in BODE index quartiles with maximum score for BODE 
quartile 4 and there is a highly significant correlation between the SGRQ 
symptom and activity score  with BODE quartiles (Pvalue<.001**)  
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Table no: 6 Comparison between SGRQ impact scores  
and BODE index 
Bode 
index 
quartil
es 
N Mean Std. Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean  
     
Lower 
Bound 
Upper 
Bound 
P 
value 
0-2 5 33.4380 10.63967 4.75821 20.2271 46.6489  
3-4 
14 57.8214 9.86173 2.63566 52.1274 63.5154 
<.001
** 
5-6 25 67.9280 5.56951 1.11390 65.6290 70.2270  
7-10 6 84.8200 6.01695 2.45641 78.5056 91.1344  
Total 50 63.6762 14.86575 2.10234 59.4514 67.9010  
 
 
In the study group SGRQ impact scores similar to activity and 
symptom score progressively increased with BODE index quartiles , with 
maximum SGRQ impact score for BODE index quartile 4 and two shows 
a highly significant correlation (pvalue<.001**) 
 
 
 
 
 
 
 
72 
 
 
 
Table no:7   Comparison between SQRQ total scores  
and BODE index 
Bode 
index 
quartil
es N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
 
P value 
     
Lower 
Bound 
Upper 
Bound 
 
 
0-2 5 39.9280 8.61820 3.85417 29.2271 50.6289  
3-4 14 59.1050 5.58871 1.49365 55.8782 62.3318  
5-6 25 70.3276 3.92776 .78555 68.7063 71.9489 < 0.001** 
7-10 6 84.4067 5.91497 2.41478 78.1993 90.6140  
Total 50 65.8348 12.62675 1.78569 62.2463 69.4233  
 
 
In the study group, The SGRQ total score increases with BODE 
index quartiles and there is a very strong correlation is found between the 
two (p value<.001**) 
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Table no: 8 Comparison of BODE index with CRP levels 
 
 
 
 
 
 
 
Table No :9 Comparison Gold stages with Crp levels 
Gold Stage Pearson Correlation .447(**) 
 Sig. (2-tailed) .001 
 N 50 
P value <.005**  
 
In the study group, on comparing CRP levels with BODE index 
and GOLD stages both exhibited highly significant correlation with CRP 
levels but GOLD staging had a weaker correlation (p value<.005**) 
compared BODE index.(p value<.001**) 
 
 
Variable  Serum CRP 
levels(mg/L) 
Bode Index Scores Pearson Correlation 
.790(**) 
 Sig. (2-tailed) 
.000 
 N 50 
P value  
<.001** 
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Table no : 10 Comparison of BODE index and GOLD  
stages with prognostic factors 
 
Prognostic factors  
Bode 
Index 
Scores 
Gold Stage 
Pack Years Pearson Correlation .335(*) .326(*) 
 Sig. (2-tailed) .028 .033 
 N 43 43 
P value  <.05* <.05* 
Duration of illness Pearson Correlation .731(**) .550(**) 
 Sig. (2-tailed) .000 .000 
 N 50 50 
P value  <.001** <.001** 
No of Annual 
Exacerbation 
Pearson Correlation 
.685(**) .376(**) 
 Sig. (2-tailed) .000 .007 
 N 50 50 
P value  <.001** <.010* 
6 Minute Walking 
Distance (M) 
Pearson Correlation 
-.823(**) -.398(**) 
 Sig. (2-tailed) .000 .004 
 N 50 50 
P value  <.001** <.005** 
 
 
 
75 
 
 
 
In the study group (table no.10) comparison was made between 
BODE index and GOLD stages with respect to prognostic factors.  
 
 Both BODE index and GOLD stages had significant correlation 
with no pack years smoked (p value<.05) but the BODE index 
correlated better. 
 Both BODE index and GOLD stages had highly significant 
correlation with the duration of illness(p value<.001**) 
 With respect to the annual exacerbations, both BODE index and 
GOLD stages had a highly significant correlation , but BODE 
index exhibited a higher correlation( p value<.001**) than GOLD 
staging(p value<.005**) 
 On comparing the relation of 6- minute walking distance with 
GOLD staging and BODE index, both showed a negative 
correlation. 
 
The decline of 6- MWD was better correlated with increase 
in BODE scores (p value<.001**) than with increase in  GOLD 
stages(p value<.005**) 
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Table no: 11 Comparison between SGRQ scores and post 
bronchodilator FEV1 
SGRQ scores  
Post 
bronchodilato
r FEV1 (L) 
SGRQ - Symptoms Pearson Correlation -.378(**) 
 Sig. (2-tailed) .007 
 N 50 
P value  <.01** 
SGRQ - Activity Pearson Correlation -.415(**) 
 Sig. (2-tailed) .003 
 N 50 
P value  <.005** 
SGRQ - Impact Pearson Correlation -.398(**) 
 Sig. (2-tailed) .004 
 N 50 
P value  <.005** 
SGRQ - Total Pearson Correlation -.418(**) 
 Sig.(2 –tailed) .002 
 N 50 
P value  <.005** 
 
 
In the study group it was found post bronchodilator FEV1 had a 
negative correlation with SGRQ activity score, (p value< .005)), Impact 
score (p value< .005) total score (p value <.005), symptom score  
(p value<.01). Among activity, impact and symptom score, better 
correlation was found between FEV1 and SGRQ activity scores. 
  
 
 
DISCUSSION 
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DISCUSSION 
 
1) In the study of M Polatlı et al92, The mean age  of the study 
candidates were (standard deviation; SD) 63.3 (9.3) years with 
59.0% of the patients under the age of 65, and 89.9% of the 
participants were male. In our study the mean age was 62.16 , 88 % 
were males and 40 % was below 60 years. 
2) In a study conducted by Kian-Chung Ong93  the male : female ratio 
of incidence was 9:1 . In our study the incidence in male: female 
ratio is 7.3:1 
3) Antonelli-Incalzi et al94 conducted a study in which it was found 
that GOLD staging in COPD  correlated with Health related quality 
of life between stages 2 and 3. In our study mostof the patients 
belonged to GOLD stages 2 and 3 and there was a highly 
significant correlation between GOLD stages and health related 
quality of life. 
4) Sarkar SK et al95showed in their study that Higher BODE quartiles 
were associated with higher (worse) SGRQ scores .In our study 
also SGRQ scores increased with increase in BODE quartile and 
the two had a highly significant association.  
5) In study conducted by Alseedi et al96 it was found that FEV1  
correlated poorly with exacerbation frequency .In this study it is 
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found that even though there an association between FEV1 and 
number of exacerbations, it is weaker compared to the association 
with BODE index quartiles. 
6) The study by Nurhan Sarioglu et al97 showed thatCRP levels have a 
weak but statistically significant correlation with BODE index. In 
this study BODE index is found to have a highly significant 
correlation with CRP levels. 
7) In the study conducted by Marin et al98 there was found to be a 
significant correlation between 6MWD and MMRC, COPD stage 
according to GOLD and PFT parameters. In this study also 6-
MWD was found have a highly significant correlation with COPD 
staging according to GOLD, but compared to BODE index this 
association was weaker. 
8) Study conducted by Funda Aksu et al99 showed that, CRP levels 
are raised even in stable COPD patients independent of smoking 
behavior. In this study also serum CRP levels are raised and the 
mean value is 14.17 mg/l consistent with previous studies 
9) In a study conducted by Reshu Agarwal et al100  it was found that 
CRP levels correlated well with FEV1  and hence GOLD staging. 
In this study also there is a highly significant correlation between 
GOLD stages and serum CRP levels. 
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CONCLUSION 
 
In our study it was found that  
 
 both BODE Index  and GOLD staging of COPD had a highly 
significant correlation with health related quality of life 
 
 Serum CRP levels were elevated in stable COPD patients and 
correlated with BODE index and Gold staging of COPD, but 
BODE index had a stronger association to CRP levels. 
 
 BODE index had a stronger correlation with cumulative number of 
pack years smoked and number of annual exacerbation compared 
to GOLD staging. 
 
 
 
 
 
 
 
  
 
 
LIMITATIONS 
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LIMITATION OF THE STUDY 
 
 The number of patients included in this study was less, and it 
should be done involving larger number of patients 
 
 The percentage of female patients were less in this study and it 
might not reflect the prevalence of COPD in females in India. 
 
 Presence of Depression and anxiety were not assessed in this study, 
which are major comorbidities associated with COPD. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
BIBLIOGRAPHY 
  
BIBLIOGRAPHY 
1) (http://www.goldcopd.com/) 
2) American thoracic society. Standards for the diagnosis and care of 
patients with Chronic Obstructive pulmonary disease. Am J Respir 
Crit Care Med 1995;152:S77-121 
3) Siafakas NM, Vermeire P, Pride NB, et al . Optimal assessment 
and management of Chronic obstructive pulmonary disease. The 
European respiratory society task force.Eur Respir J 1995;81398-
420 
4) Global strategy for diagnosis management and prevention of 
COPD available at www.gold.copd.org((7,8NA p8). 
5) Celli BR, MacNee W Standardsfor the diagnosis and treatment of 
patients with COPD Eur Respir J 2004;23(6):932-46 
6) Albert P augustiA, EdwardL et al .Bronchodilator response as a 
phenotypic characteristic of established COPD,Thorax 2012;67 
(8):701-8(12,AN p 8) 
7) Soriano J B , Coleman B et al, The proportional venn diagram of 
COPD :two approximations from US and UK Chest 2003;124(2) 
478-81 
8) Shaya FT, Dongyi D, et al Burden of concomitant asthma and 
COPD in a Medicaid population Chest 2008134(1):14-9 
9) Buist A12. S, McBurnie MA, Vollmer WM, Gillespie S, Burney P, 
Mannino DM, et al. BOLD Collaborative Research Group. 
International variation in the prevalence of COPD (the BOLD 
Study): a population-based prevalence study. Lancet 2007; 370 : 
741-50. ( 12, p 252 indian) 
10) Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic 
obstructive pulmonary disease prevalence, incidence, and mortality 
in Ontario, Canada, 1996 to 2007: a population-based study. Arch 
Intern Med. 2010;170(6):560–565. 
11) Kabir Z, Connolly GN, Koh HK, Clancy L. Chronic obstructive 
pulmonary disease hospitalization rates in Massachusetts: a trend 
analysis. QJM. 2010;103(3):163–168. 
12) Tan WC, Seale P, Ip M, et al. Trends in COPD mortality and 
hospitalizations in countries and regions of Asia-Pacific. 
Respirology. 2009;14(1):90–97. 
13) Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive 
pulmonary disease:current burden and future projections. Eur 
Respir J 2006;27:397-412. (2 page 298 iceberg) 
14) Wig KL, Guleria JS, Bhasin RC, Holmes E Jr, VasudeV,YL.Singh 
H. Certain clinical and epidemiological patterns of chronic 
obstructive lung disease as seen in Northern India. Indian J Chest 
Dis 1964; 6 : 183-94. 
15) Jindal SK. A field study on follow up at 10 years of prevalence 18. 
of chronic obstructive pulmonary disease & peak expiratory flow 
rate. Indian J Med Res 1993; 98 : 20-6. 
16) Thi19. ruvengadam KV, Raghava TP, Bhardwaj KV. Survey of 
prevalence of chronic bronchitis in Madras city. In: Viswanathan 
R, Jaggi OP, editors. Advances in chronic obstructive lung disease. 
Delhi: Asthma and Bronchitis Foundation of India; 1977. p. 59-6. 
17) Ray D, Abel R, Selvaraj KG. A 5-yr prospective epidemiol-20. 
ogical studyof chronic obstructive pulmonary disease in rural 
South India. Indian J Med Res 1995; 101 : 238-44. 
18) Jindal SK, Aggarwal AN, Gupta D, Agarval R, Kumar R, Kaur 21. 
T, et al. Indian study on epidemiology of asthma, respiratory 
symptoms and chronic bronchitis in adults (INSEARCH). Int J 
Tuberc Lung Dis 2012; 16 : 1270-7 
19) Murthy KJR, Sastry JG. Economic burden of chronic obstructive 
pulmonary disease: NCMH Background Papers- Burden of Disease 
in India, 2005. Available online: http://whoindia.org/LinkFiles/ 
20) GanWQ, Man SF, SEnthilselvan A et al. Association between 
COPD and systemic inflammation a systemic reviewand meta 
analysis.Thorax 2004;59:574-80 
21) van Eden  SF, Sin DD.COPD:a chronic systemic infalammatory 
disease. Respiration2008;75:224-38 
22) Thomsen M Dahl M,Lange Pet al Inflammatory biomarkers and 
comorbidities in COPD.Am J Rspir Crit Care Med 
2012;186(10):982-8 
23) Fogarty AW,Jones S briton JRet al Systemic inflammation and 
decline in lung functionin a general population a prospective study 
thorax2007;62:515-20 
24) Groenewegen KH,Postma DS, Hop WC et alIncreased systemic 
inflammation is a risk factor for COPD exacerbationChest 
2008;133:350-7 
25) Donaldson GC, SeemungalTA, PatelIS,et al.Airway and systemic 
inflammation and decline in lung function in patients with 
COPDChest 2005;128:1995-2004 
26) Sin DD, Leung R,Gan WQ,et al .circulating surfactant protein D as 
a potential lung specific biomarker of health outcomes in COPD:a 
pilot studyBMC pulm med 2007;7:13 
27) BhowmikA,Seemungal TA, Sapsford RJet al Repletion of sputum 
inflammatory markers and lung function changes in COPD 
exacerbations Thorax 2000;55(2):114-20 
28) Takabatake N, nakamura Het al, The relation between chronic 
hypoxemia and activation of Tumor necrosis factor alphasystem in 
patients with COPD Am J Respir Crit Care Med 2000;161:1179-84 
 
29) Voynow JA, Gendler SJ, Rose MC: Regulation of mucin genes in 
chronic inflammatory airway diseases. Am J Respir Cell Mol Biol 
34:661–665, 2006 
30) Baginski TK, Dabbagh K, Satjawatcharaphong C, et al: Cigarette 
smoke synergistically enhances respiratory mucin induction by 
proinflammatory stimuli. Am J Respir Cell Mol Biol 35:165–174, 
2006.  
31) Hogg JC, Macklem PT, Thurlbeck WM: Site and nature of 
airwaysobstruction in chronic obstructive lung disease. N Engl J 
Med 278:1355–1360, 1968. 
32) Cosio M, Ghezzo H, Hogg JC, et al: The relationship between 
structural changes in small airways and pulmonary-function tests. 
N Engl J Med 298:1277–1281, 1978. 
33) Saetta M, Turato G, Luppi F: Inflammation in the pathogenesis of 
chronic obstructive pulmonary disease. In Voekel NF, MacNee W, 
editors: Chronic obstructive lung disease, Ontario, 2002, BC 
Decker, pp 114–126. 
34) Saetta M, Turato G, Baraldo S, et al: Goblet cell hyperplasia and 
epithelial inflammation in peripheral airways of smokers with both 
symptoms of chronic bronchitis and chronic airflow limitation. Am 
J Respir Crit Care Med 161:1016–1021, 2000. 
 
35) Saetta M, Di Stefano A, Turato G, et al: CD8+ T-lymphocytes in 
peripheral airways of smokers with chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 157:822–826, 1998. 
36) Fletcher C, Peto R: The natural history of chronic airflow 
obstruction. Br Med J I:1645–1648, 1977. 
37) Shao MXG, Nakanaga T, Nadel JA: Cigarette smoke induces 
MUC5AC mucin overproduction via tumor necrosis factor-α-
converting enzyme in human airway epithelial (NCI-H292) cells. 
Am J Physiol Lung Cell Mol Physiol 287:L420–L427, 2004. 
38) Snider GL, Kleinerman LJ, Thurlbeck WM, et al: The definition of 
emphysema: report of a National Heart Lung and Blood Institute, 
Division of Lung Diseases Workshop. Am Rev Respir Dis 
132:182– 185, 1985. 
39) Rodriguez-Roisin R. Toward a consensus definition of COPD 
exacerbations. Chest '$$$ ; !!( : %;"S -=$!S. 
40) Hogg JC, Chu F, Utokaparch S, et al: The nature of small airway 
obstruction in chronic obstructive pulmonary disease. N Engl J 
Med 350:2645–2653, 2004. 
41) Hogg JC, Chu FS, Tan WC, et al: Survival after lung volume 
reduction in chronic obstructive pulmonary disease: insights from 
small airway pathology. Am J Respir Crit Care Med 176:454–459, 
2007. 
42) Di Stefano A, Caramori G, Ricciardolo FL, et al: Cellular and 
molecular mechanisms in chronic obstructive pulmonary disease: 
an overview. Clin Exp Allergy 34:1156–1167, 2004. 
43) O’Shaughnessy TC, Ansari TW, Barnes NC, et al: Inflammation in 
bronchial biopsies of subjects with chronic bronchitis: inverse 
relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit 
Care Med 155:852–857, 1997. 
44) Ollerenshaw SL, Woolcock AJ: Characteristics of the inflammation 
in biopsies from large airways of subjects with asthma and subjects 
with chronic airflow limitation. Am Rev Respir Dis 145:922–927, 
1992. 
45) Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the 
diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary. Am J Respir Crit 
Care Med 2007;176(6):532–55. 
46) From the global strategy for the diagnosis, management and 
prevention of COPD. 2011. Available at: http://www.goldcopd 
.org/. Accessed April 1, 2012. 
47) Joo MJ, Au DH, Lee TA. Use of spirometry in the diagnosis of 
chronic obstructive pulmonary disease and efforts to improve 
quality of care. Transl Res 2009;154(3): 103–10. 
48) Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of 
COPD in asymptomatic elderly never-smokers. Eur Respir J 
2002;20(5):1117–22. 
49) Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of 
normal for the FEV1/FVC ratio reduces the misclassification of 
airway obstruction. Thorax 2008;63(12):1046–51. 
50) Cerveri I, Corsico AG, Accordini S, et al. Underestimation of 
airflow obstructionamong young adults using FEV1/FVC <70% as 
a fixed cut-off: a longitudinal evaluation of clinical and functional 
outcomes. Thorax 2008;63(12):1040–5. 
51) Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive 
pulmonary disease in the older adult: what defines abnormal lung 
function? Thorax 2007;62(3):237–41. 
52) Lin SH, Kuo PH, Kuo SH, et al. Severity staging of chronic 
obstructive pulmonarydisease: differences in pre- and post-
bronchodilator spirometry. Yonsei Med J 2009;50(5):672–6. 
53) Jing JY, Huang TC, Cui W, et al. Should FEV1/FEV6 replace 
FEV1/FVC ratio to detect airway obstruction? a metaanalysis. 
Chest 2009;135(4):991–8. 
54) Martinez FJ, Raczek AE, Seifer FD, et al: Development and initial 
validation of a self-scored COPD Population Screener 
Questionnaire (COPD-PS). COPD 5(2):85–95, 2008. 
55) ATS statement: guidelines for the six-minute walk test. Am J 
Respir Crit Care Med 166(1):111–117, 2002. 
56) Solway S, Brooks D, Lacasse Y, Thomas S: A qualitative 
systematic overview of the measurement properties of functional 
walk tests used in the cardiorespiratory domain. Chest 119(1):256–
270, 2001. 
57) Fishman A, Martinez F, Naunheim K, et al: A randomized trial 
comparing lung-volume-reduction surgery with medical therapy 
for severe emphysema. N Engl J Med 348(21):2059–2073, 2003. 
58). Belman MJ: Exercise in patients with chronic obstructive 
pulmonary disease. Thorax 48(9):936–946, 1993. 
59) American Thoracic Society/European Respiratory Society 
statement: standards for the diagnosis and management of 
individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit 
Care Med 168(7):818–900, 2003. 
60). Martinez FJ, Han MK, Flaherty K, Curtis J: Role of infection and 
antimicrobial therapy in acute exacerbations of chronic obstructive 
pulmonary disease. Expert Rev Anti Infect Ther 4(1):101–124, 
2006. 
61) Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha 
JA. Usefulness of the Medical Research Council (MRC) dyspnoea 
scale as a measure of disability in patients with chronic obstructive 
pulmonary disease. Thorax 1999;54:581-6. 
62) Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A 
selfcomplete measure for chronic airflow limitation - the St 
George’s Respiratory Questionnaire. Amer Rev Respir Dis 
1992;145:1321-7 
63) Miller MR, Hankinson J, Brusasco V, et al. Standardisation of 
spirometry. Eur Respir J 2005;26:319-38. 
64) 509, 510 p 13) van der Molen T, Willemse BW, Schokker S, ten 
Hacken NH, Postma DS, Juniper EF. Development, validity and 
responsiveness of the Clinical COPD Questionnaire.Health Qual 
Life Outcomes. 2003 Apr 28;1:13 
65) Reda AA, Kotz D, Kocks JW, Wesseling G, van Schayck CP. 
Reliability and validity of the clinical COPD questionniare and 
chronic respiratory questionnaire. Respir Med 2010 
Nov;104(11):1675-82. 
66) Miravitlles M, Soriano JB, García-Río F, Muñoz L, Duran- 
Tauleria E, Sanchez G, et al. Prevalence of COPD in Spain: impact 
of undiagnosed COPD on quality of life and daily life activities. 
Thorax. 2009;64(10):863-8. 
67) Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators 
for chronic obstructive pulmonary disease: indacaterol versus 
tiotropium. Am J Respir Crit Care Med 2010;182:155-62. 
68) Vincken W, van Noord JA, Greefhorst AP, et al. Improved health 
outcomes in patients with COPD during 1 yr's treatment with 
tiotropium. Eur Respir J 2002;19:209-16. 
69). Hansell AL, Walk JA, Soriano JB: What do chronic obstructive 
pulmonary disease patients die from? A multiple cause coding 
analysis. Eur Respir J 22(5):809–814, 2003. 
70) Han MK, McLaughlin VV, Criner GJ, Martinez FJ: Pulmonary 
diseases and the heart. Circulation 116(25):2992–3005, 2007. 
71) Bolton CE, Ionescu AA, Shiels KM, et al: Associated loss of fat-
free mass and bone mineral density in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 170(12):1286–
1293, 2004. 
72) Nuti R, Siviero P, Maggi S, et al: Vertebral fractures in patients 
with chronic obstructive pulmonary disease: the EOLO Study. 
Osteoporos Int 20(6):989–998, 2009. 
73) Mannino DM, Thorn D Swensen A et al Prevalence and outcomes 
of diabetes, hypertension and cardiovascular disease in COPD.Eur 
Respir J 2008;32(4)962-9 
74) Marin JM, Soriano JB, Carrizo SJ, et al: Outcomes in patients with 
chronic obstructive pulmonary disease and obstructive sleep apnea: 
the overlap syndrome. Am J Respir Crit Care Med 182(3):325–
331, 2010. 
75) Terada K, Muro S, Sato S, et al: Impact of gastro-oesophageal 
reflux disease symptoms on COPD exacerbation. Thorax 
63(11):951–955, 2008. 
76) Hanania NA, Mullerova H, Locantore NW, et al: Determinants of 
depression in the ECLIPSE chronic obstructive pulmonary disease 
cohort. Am J Respir Crit Care Med 183(5):604–611, 2011. 
77) Gottlieb SS, Mccarter RJ,Vogel RA.Effect of beta blockade on 
mortality among high risk and low risk patients afer MI.N Engl J 
Med 1998;339(8)::489-97 
78) (96,97 p 107 NAWust RC,Dengens H . factors contributing muscle 
wasting and dysfunction in COPD patients.Int J Chron Obstruct 
Pulmon Dis 2007;2:289-300 
79).Prudue MP, Gold et alImpaired lung function and incidence of lung 
cancer in a cohort of Swedish construction workers. Thorax 
2007;62(1):51-6 
80) Danesh J.Lewington S et alPlasma fibrinogen levels and the risk of 
major cardiovascular diseases and non vascular mortality;an 
individual participant meta analysis.JAMA2005;294:1799-809 
81) Horsfall LJ,Rait G et al serum bilirubin and riskofrespiratory 
disease and death. JAMA 2011;305:691-7 
82) Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow 
obstruction, dyspnea, and exercise capacity index in chronic 
obstructive pulmonary disease. N Engl J Med 2004; 350:1005. 
83) Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in 
the BODE index predicts mortality in severe emphysema. Am J 
Respir Crit Care Med 2008; 178:491 
84) Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight 
in chronic obstructive pulmonary disease. The National Institutes 
of Health Intermittent Positive-Pressure Breathing Trial. Am Rev 
Respir Dis 1989; 139:1435. 
85) Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body 
mass, and prognosis in patients with chronic obstructive pulmonary 
disease from a random population sample: findings from the 
Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 
173:79. 
86) Fishman A, Martinez F, Naunheim K, et al. A randomized trial 
comparing lung-volume-reduction surgery with medical therapy 
for severe emphysema. N Engl J Med 2003; 348:2059. 
87) (287-289 M&N p 784) Rodriguez-Roisin R: Toward a consensus 
definition for COPD exacerbations. Chest 117(5 Suppl 2):398s–
401s, 2000. 
88) Burge S, Wedzicha JA: COPD exacerbations: definitions and 
classifications. Eur Respir J Suppl 41:46s–53s, 2003. 
 89) (290) Sethi S, Wrona C, Grant BJ, Murphy TF: Strain-specific 
immune response to Haemophilus influenzae in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 169(4):448–453, 
2004. 
90) Turner MO, Patel A, Ginsburg S, FitzGerald JM: Bronchodilator 
delivery in acute airflow obstruction. A meta-analysis. Arch Intern 
Med 157(15):1736–1744, 1997. 
91) Leuppi JD, Schuetz P, Bingisser R, et al: Short-term vs 
conventional glucocorticoid therapy in acute exacerbations of 
chronic obstructive pulmonary disease: the REDUCE randomized 
clinical trial. J Am Med Assoc 309(21):2223–2231, 2013. 
92) Polatlı Met al : A cross sectional observational study on the 
influence of chronic obstructive pulmonary disease on activities of 
daily living: the COPD-Life study. Tuberk Toraks 2012;  
60(1): 1-12  
93) Kian-Chung Ong1Does the multidimensional grading system 
(BODE) correspond to differences in health status of patients with 
COPD? International Journal of COPD 2006:1(1) 91–96  
94)AntonelliIncalzi R, Imperiale C, Bellia V, Catalano F, Scichilone 
N, Pistelli R, et al. Do GOLD stages of COPD severity really 
correspond to differences in health status? Eur Respir J 
2003;22:444-9. 
95) Sarkar SK, Basuthakur S, Das SK, Das A, Das S, Choudhury S, et 
al. Evaluation of correlation of BODE index with health-related 
quality of life among patients with stable COPD attending a 
tertiary care hospital. Lung India 2015;32:24-8. 
96) The effects of inhaled corticosteroids in chronic obstructive 
pulmonary disease: a systematic review of randomized placebo-
controlled trials Am J Med 2002 Vol 113 (59-65) 
97) Sarioglu N1, Alpaydin AO, Coskun AS, Celik P, Ozyurt 
BC, Yorgancioglu A. Relationship between BODE index, quality 
of life and inflammatory cytokines in COPD patients.Multidiscip 
Respir Med. 2010 Apr 30;5(2):84-91. doi: 10.1186/2049-6958-5 
-2-84. 
98) Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. 
Inspiratory capacity, dynamic hyperinflation, breathlessness, and 
exercise performance during the 6- minute-walk test in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 
2001;163:1395-1399. 
99) Funda Aksu1 , Nermin Çapan1 , Kurtuluş Aksu1 , Ruhsar 
Ofluoğlu1 , Sema Canbakan1 , Bünyamin Yavuz2 , Kadir Okhan 
Akin3 C-reactive protein levels are raised in stable Chronic 
obstructive pulmonary disease patients independent of smoking 
behavior and biomass exposureJ Thorac Dis 2013;5(4):414-421. 
doi: 10.3978/j.issn.2072-1439.2013.06.27 
100) Agarwal et al. Multidisciplinary Respiratory Medicine 2013, 8:63 
  
 
 
ANNEXURES 
  
ABBREVIATIONS 
COPD : Chronic Obstructive Pulmonary Disease 
FEV1  : Forced Expiratory Volume in the first second 
FVC  : Forced Vital Capacity 
ATS  : American Thoracic Society 
ERS  : European Respiratory Society 
GOLD : Global Initiative for Chronic Obstructive Lung  
   Disease 
CRP  : C- Reactive Protein 
WHO  : World Health Organisation 
CDC  : Centers for disease Control and Prevention 
AAT  : Alpha 1 Antitrypsin 
AHR  : Airway Hyperresponsiveness 
SAA  : Serum Amyloid A 
SP-D  : Surfactant protein D 
LPS  : Lipopolysaccharide 
PaO2  : Partial pressure of oxygen in blood 
LLN  : Lower Limit of Normal 
RV  : Residual Volume 
TLC  : Total lung capacity 
DLCO : Diffusion Capacity for Carbon Monoxide 
6-MWT : 6-minute walk test 
6-MWD : 6-minute walk distance 
CPET  : Cardio Pulmonary Exercise Test 
LVRS : Lung Volume Reduction surgery 
SGRQ :  St George Respiratory Questionnaire 
CAT  : COPD assessment test 
BMI  : Body Mass Index(kg/m2) 
mBODE : Modified Bode Index 
FFT  : Fat free mass index 
IGCS  : Inhaled Glucocorticoids 
PDE-4 : Phosphodiesterase-4 
 
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
OP/ NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
 
PAST HISTORY   : 
MI in past six months 
Active TB 
History of Atopy 
Rheumatological 
diseases 
Number of annual 
exacerbation 
Number of 
hospitalization 
 
 
 
TREATMENT HISTORY : 
 
DRUG ALLERGY  : 
 
GENERAL EXAMINATION  
Pallor:               Icterus:            Cyanosis:           Clubbing:          
Lymphadenopathy:        Odema: 
 
VITALS 
     Pulse Rate:          BP:          Respiratory rate:            Temperature: 
 
SYSTEMIC EXAMINATION 
 
CARDIOVASCULAR SYSTEM: 
 
 
RESPIRATORY SYSTEM   : 
 
 
ABDOMEN           : 
 
CENTRAL NERVOUS SYSTEM 
 
SPIROMETRY: 
C-REACTIVE PROTEIN LEVEL: 
 
BODE INDEX: 
                    BODY MASS INDEX (KG/M2 ) – 
                    FEV1( % of predicted)                  - 
                    6- mt walking distance                  - 
                    MMRC dyspnea grade (scale)      - 
 
 
ST. GEORGE RESPIRATORY QUESTIONAIRE(SGRQ) SCORE: 
 
 
 
INFORMATION SHEET 
We are conducting a study on  “COMPARISON BETWEEN 
BODE INDEX AND GOLD STAGING WITH RESPECT TO 
QUALITY OFLIFE AND C-REACTIVE PROTEIN LEVELS IN 
COPD PATIENTS” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your co- operation to 
undergo Pulmonary function test, 6-minute walk test and your blood 
sample may be valuable to us. 
The purpose of this study is to investigate relationship between 
GOLD STAGING, BODE index and its components with serum C 
reactive protein levels quality of life as well as with prognostic factors 
like disease duration, annual exacerbation and hospital rates . 
We are selecting certain cases and if you are found eligible, we 
would like to perform extra tests and special studies which in any way do 
not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of Investigator   Signature / left thumb impression  
      of participant 
 
Date: 
Place: 
 
  
PATIENT CONSENT FORM 
Study Detail : “COMPARISON BETWEEN BODE INDEX AND 
GOLD STAGING WITH RESPECT TO QUALITY 
OF LIFE AND C-REACTIVE PROTEIN LEVELS 
IN COPD PATIENTS”  
Study Centre : Department of Thoracic Medicine, Rajiv Gandhi 
Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any ❏ 
data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration 
in my health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination ,and 
necessary investigations. 
 
Study investigators                                            Patients name 
 
name and signature                Signature or thumb impression 
 
Dr AISWARYA DHANAPALAN  
 
 
  
Nehahspapd; ngah;:; ;; ;; ;  
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SYMPTOMSACTIVITYIMPACT TOTAL
1 RADHAKRISHNAN 65 M 20 4 2 2 8 1.27 68 2.81 170 65 21.84 300 2 2 1 2 41.95 59.46 44.54 48.63
2 ELUMALAI 68 M 26 6 3 3 16 1.3 47 1.89 165 53 19.46 230 2 6 3 3 65.74 72.82 73.5 72
3 SENGUTHUVAN 66 M 22 4 1 1 7 1.64 61 2.42 168 65 23.8 380 1 1 1 2 32.85 41.73 28.54 33.25
4 SARANGAPANI 70 M 30 7 4 4 15 1.15 46 2.55 158 52 20.8 230 3 7 4 3 67.67 78.96 79.16 77.19
5 NATARAJAN 63 M 20 3 1 1 7.56 1.53 71 2.91 160 58 22.6 380 1 0 1 2 37.55 41.73 20.75 29.9
6 ABDUL JAFFER 66 M 20 4 3 3 4.5 1.43 59 2.83 168 59 20.9 290 2 4 2 2 67.46 53.62 55.03 56.73
7 SWAMINATHAN 64 M 18 3 3 3 10.56 1.53 64 2.75 158 53 21.23 200 2 4 2 2 51.79 57.84 64.86 60.54
8 RAJA 63 M 14 3 2 2 7.89 1.62 68 2.82 160 55 21.48 300 1 1 1 2 38.31 57.84 28.82 39.23
9 VELAYUDHAN 68 M 18 4 2 2 11.26 1.42 58 2.41 155 53 22.06 200 2 4 2 2 61.55 61.05 54.29 57.6
10 SAMIVEL 70 M 24 5 3 3 13.3 1.47 62 2.43 158 56 22.4 150 3 4 2 2 61.55 66.89 66.89 62.84
11 VETRIVEL 65 M 22 5 2 2 16.79 1.33 55 2.75 160 56 21.87 180 2 4 2 2 59.18 72.89 62.42 65.16
12 SAKUNTHALA 55 F 5 3 3 15.45 1.32 67 2 152 45 19.87 200 3 5 3 2 61.55 71.33 70.29 69.09
13 VENKATESAN 66 M 22 6 4 4 20.21 1.35 58 2.93 163 55 20.7 150 3 6 3 2 71.85 78.22 79.24 77.67
14 MANI 63 M 20 6 4 4 17.54 1.53 55 2.92 168 56 19.84 180 3 6 3 2 76.71 72.82 68.61 71.23
15 DURAIRAJ 66 M 22 7 5 5 15.38 1.36 54 2.81 163 54 20.32 150 3 6 3 3 63.95 92.51 60.46 70.92
16 KRISHNAMOORTHI 65 M 24 4 3 1 11.52 0.95 60 1.89 162 56 21.33 280 3 4 2 2 63.62 66.19 62.57 63.84
17 ELUMALAI 57 M 26 5 2 1 15.32 1.25 51 2.84 165 52 19.1 160 3 6 3 2 79.09 72.82 68.21 71.45
18 DEVATHASAN 55 M 24 3 2 1 12.24 1.31 54 2.53 158 48 19.22 260 2 4 2 2 51.79 57.84 64.86 60.54
19 KAMALA 52 F 6 3 1 26.7 0.95 46 1.82 155 46 1914 150 3 7 4 3 81.31 85.81 76.53 80.13
20 MUNUSAMY 66 M 26 5 4 2 16.32 1.33 58 2.54 160 52 30.31 200 3 6 3 2 83.2 79.67 69.73 74.98
21 RAMDOSS 58 M 18 5 3 1 7.32 1.12 53 2.71 158 54 21.63 240 2 4 2 2 56.69 60.56 70.52 65.2
22 SARAVANAN 56 M 20 5 4 1 18.33 1.23 50 2.43 162 52 19.81 180 3 6 3 2 83.2 79.67 65.43 72.72
23 MANI 68 M 22 6 3 2 14.82 1.26 56 2.61 160 50 19.53 280 3 5 3 2 75.09 66.19 61.72 65.3
24 PALANI 69 M 24 7 5 2 18.64 1.27 56 2.82 158 48 19.22 200 3 6 3 2 83.59 72.82 65.67 70.82
SGRQ SCORES
25 RANGAN 60 M 24 5 4 1 17.32 1.52 52 3.1 170 55 19.03 180 3 6 3 2 76.71 72.82 68.61 71.23
26 KESAVAN 55 M 30 4 3 1 12.31 1.35 51 2.6 164 52 19.33 260 2 4 2 2 63.62 51.54 55.79 55.88
27 RAJAMANI 65 M 22 4 2 0 11.56 1.55 62 2.9 166 50 18.14 280 2 4 2 2 63.83 60.35 58.23 59.8
28 VELAIYAMMAL 58 M 20 5 2 2 14.32 0.95 51 1.71 152 50 21.64 200 3 5 3 2 75.5 66.19 64.93 67.07
29 UNNAMALAI 54 M 18 6 3 1 16.52 1.42 54 2.95 165 52 19.1 220 2 5 3 2 70.45 66.19 60.2 63.72
30 DAKSHINAMOORTHY 58 M 22 5 3 1 15.21 1.53 63 2.85 160 53 20.7 220 3 6 3 2 79.09 72.82 65.67 71.83
31 GOVINDAN 63 M 20 4 3 1 10.11 1.3 51 2.8 165 58 21.3 280 1 3 2 2 70.35 53.62 41.23 49.82
32 ARUMUGAM 65 M 28 6 4 1 14.32 1.54 56 2.92 168 55 19.48 230 2 5 3 2 75.09 59.46 65.68 65.36
33 SELVI 54 F 4 3 1 10.31 1.1 56 2.1 155 53 22.06 300 2 3 2 2 54.48 66.19 36.96 48.73
34 MAHALAKSHMI 60 M 5 3 1 12.31 0.95 58 2.12 150 48 21.3 300 2 3 2 2 63.35 66.19 49.47 54.24
35 RAJAMANI 65 M 30 6 5 2 17.61 1.35 56 2.9 168 55 19.48 200 3 6 3 2 77.48 72.82 74.45 74.46
36 RAMAMOORTHY 68 M 24 4 3 1 10.23 1.45 67 2.63 158 52 20.82 250 1 2 1 2 41.95 59.46 44.54 48.63
37 GANESAN 63 M 22 5 5 2 15.87 1.27 54 2.67 160 50 19.53 180 2 5 3 2 72.66 66.19 60.08 64.02
38 MUNUSAMY 60 M 18 4 5 2 16.37 1.43 54 2.9 164 52 19.33 200 3 6 3 2 75.09 72.82 78.31 76.11
39 CHELLAN 69 M 24 6 6 3 16.92 0.9 40 2.43 160 48 18.75 140 3 7 4 3 82.38 79.67 88.63 84.56
40 ARUMUGAM 54 M 20 4 4 1 8.13 1.37 56 2.68 158 50 20.02 250 2 4 2 2 67.67 66.19 66.38 66.55
41 ELLAPPAN 64 M 24 5 4 1 7.19 1.35 58 2.63 162 52 19.81 250 2 5 3 2 75.09 66.19 64.31 66.67
42 ELUMALAI 63 M 22 5 4 1 14.53 1.29 51 2.7 164 55 20.44 230 2 5 3 2 75.09 66.19 66.85 68.02
43 MUHAMMED 58 M 20 4 3 2 17.5 1.39 57 2.67 160 53 20.7 200 2 5 3 2 70.09 66.19 66.85 67.33
44 CHANDRAN 62 M 28 5 4 2 13.26 1.28 55 2.76 162 54 20.57 220 2 5 3 2 75.09 72.82 67.12 70.17
45 KESAVAN 58 M 22 5 5 3 17.66 1.19 49 2.75 156 48 19.72 200 3 7 4 3 79.96 79.67 84.04 82
46 DEVATHASAN 55 M 16 4 4 2 16.31 1.29 53 2.8 160 53 20.7 220 2 5 3 2 70.09 72.82 64.86 68.28
47 LAKSHMI 60 F 5 4 2 17.46 0.85 50 1.89 152 45 19.47 200 3 6 3 2 77.48 72.82 80.3 77.57
48 VASANTHA 58 F 5 4 1 16.65 0.96 53 1.92 150 46 20.44 200 2 5 3 2 75.09 72.82 67.12 70.17
49 PALANISAMY 70 M 30 7 6 3 19.64 1.26 47 2.5 168 53 18.77 120 3 8 4 3 95.71 92.51 91.94 92.74
50 PANDURANGAN 65 M 24 6 3 2 21.3 1.12 47 2.73 164 50 18.59 140 3 8 4 3 88.74 92.51 88.62 89.82
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TURNITIN PLAGIARISM SCREENSHOT 
 
 
  
